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Abstract
The anti-cancer properties of curcumin, the natural yellow pigment in the roots of
turmeric (Curcuma longa), have been extensively described over the last century. It has been
shown to interfere with multiple cell signaling pathways, including execution of apoptosis, antiproliferation, anti-angiogenic, and anti-inflammatory properties. However, curcumin’s cytotoxic
potential is limited when administered in vivo. With the idea of preserving curcumin’s
characteristics, but improving its bioavailability, analogues have been developed and evaluated
in the last decade. Most of the analogues have shown very good anti-cancer activity in various
cell lines and one analogue is now in a clinical trial. Nonetheless, this analogue acts through
redox-dependent mechanism in MDA-MB-231 human breast cancer cells and DU-145 human
prostate cancer cells and causes necrosis in some lymphoid cancerous cells. Thus, the main scope
of my research has been the identification and characterization of a lead curcumin analogue,
from a library of compounds, as a potent apoptotic agent against leukemia and lymphoma.
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Chapter 1: Curcumin and its analogues against cancer
This first chapter describes what cancer is and proposes curcumin analogues as
therapeutic agents. Before being able to describe cancer treatments, it is essential to first
understand the nature of cancer. Furthermore, statistics and developing strategies to fight and
prevent cancer are presented.
1.1

Brief history of cancer
The first documented emergence of cancer was back in 1500 B.C. in Egypt, where eight

cases of breast lumps and the applied treatment were described on a papyrus [1]. The methods
used to destroy the lumps were surgical removal and cauterization. Around 400 B.C.,
Hippocrates described large masses or lumps protruding from breasts, neck, or nose of people.
The lumps resembled the rough exterior and hardness of crabs, thus Hippocrates named the
lumps as karkinos [2]. Hippocrates hypothesized that an excess of black bile caused these
protuberances. He also observed that some masses were not life-threatening. While dissecting
and describing breast cancer lumps, Galen of Pergamon (131-201, A.D.), found swollen veins all
around the masses. Around 47 B.C., cancer was considered a disease and was Aulus Cornelius
Celsus who coined the latin term karkinoma to designate it. In antiquity, the causes of cancer and
its many types were unknown and observations were only made about one visible stage of the
disease.
In modern times, cancer is defined as a broad group of pathologies involving different
stages (unregulated cell growth, invasion, and metastasis). The progress of biology throughout
the years has revealed that cancer is developed by the accumulation of mutations in the DNA of
normal cells. Thus, mutations are responsible for the changes that make the cells grow in an
uncontrolled way. These mutations ultimately alter cell receptors, cell signaling pathways, cell
division, and survival rates. These combinations of alterations stimulate uncontrolled cell
proliferation forming a lump of cells called tumor. Thus, tumors can be classified into malignant
1

and benign. Malignant tumors invade nearby parts of the body and later spread to more distant
parts of the body through the lymphatic system or bloodstream (Fig. 1.1). Benign tumors do not
invade neighbor tissues and do not spread throughout the body. Although, benign tumors are not
considered cancerous, because they lack the ability to spread; they can become cancerous as
well. If a tumor is left untreated, it can spread causing a series of different health complications;
for these reasons it is considered that cancer comprehends a group of diseases.
The basis of cancer would not have been able to be elucidated without major previous
discoveries made on the genetic material. In 1860, deoxyribonucleic acid (DNA) was first
discovered by Friedrich Miescher and later in 1944 Oswald Avery and colleagues proved that
DNA is the chemical entity in which the genetic information is carried [3]. Nine years later,
Watson and Crick elucidated the double-helical structure of DNA. Interconnected nucleotides
form the DNA structure and each nucleotide is formed by a phosphate group, a deoxyribose
sugar, and a single nitrogenous base (Fig.1.2). We also know that there are two basic categories
of nitrogenous bases: the purines (adenine [A] and guanine [G]), each with two fused rings, and
the pyrimidines (cytosine [C], thymine [T], each with a single ring. A decade later, François
Jacob and Jacques-Lucien Monod postulated that base sequences in the DNA double helix coded
information for the construction of proteins. Also, that the specific sequence of those bases in
the DNA precisely determine the sequence of amino acids in proteins [4]. The sequence of amino
acids in turn determines the unique structure and function of each type of protein. Therefore, the
specification of amino acid sequence, which is accomplished by base sequences in the DNA,
provides almost all the information that is required to construct a protein (Fig. 1.3). Only about
1.5% of a mammal's genomic DNA carries sequence information that encodes the structures of
proteins and the other 98.5% of DNA is known to be "noncoding" stretches in the genome called
junk DNA [5]. Following these discoveries, the discipline of molecular biology grew up
delivering solutions to understand how the genetic constitution of cells and organism determines
its appearance and function. Thus, molecular biology and genetics offered a better understanding
2

of how cancer arises. Further findings helped in the understanding of the causative factors of
cancer. These findings lead to the conclusion that a small number of alterations in the genetic
material are needed for carcinogenesis [6]. Now we better understand that cancer originates with
the accumulation of alterations or mutations in our genetic material (Fig. 1.4).

Alfred G.

Knudson thus postulated in 1971 the “two hit hypothesis” to explain that two mutations are at
least necessary to sufficiently affect the genome and promote cancer formation [7]. One of these
mutations should be a germ line mutation (inherited from parents and contained in the germ
cells) and the other one a somatic mutation (accumulated along our life in any part of the body).
The hereditary and nonhereditary forms of cancer entail the same number of events as well.
Therefore, cancer can develop when two somatic mutations occur or two germ mutations are
inherited. These mutations comprise a wide range of alterations like deletions, translocations,
and amplifications of DNA caused by environmental factors, lifestyles, oncogenes, viruses, or
bacteria.
1.2

Chemicals, viruses, bacteria, and lifestyles as etiologic agents of cancer
Cancer can originate from the exposure to certain chemicals and environmental agents.

This was early noticed by the English physician John Hill, who in 1761 associated the excessive
use of tobacco with the development of nasal cancer [8]. Fourteen years later, Percivall Pott, a
surgeon in London, reported a considerable number of patients with cancer of the scrotum [9].
All of these patients had worked in their youth as chimney sweepers. Within three years, the
Danish sweeper’s organization urged its members to remove well with water and soap the coal
tar from their skin. This practice markedly lowered the rate of scrotal cancer in Europe. In 1916,
Katsusaburo Yamagiwa, a Japanese pathologist, succeeded in experimentally inducing cancer in
rabbits by painting their ears with coal tar [10]. In 1925, British chemists were successful in
purifying several components of coal tar that were particularly carcinogenic, as demonstrated by
the ability of these compounds to induce cancer on laboratory mice. Additional products of
combustion and causative agents of cancer, such as polycyclic aromatic hydrocarbons (33

methylcholanthrene, benzo[a]pyrene, and 1,2,4,5dibenz[a,h anthracene) were subsequently found
in the condensates of cigarette smoke as well [11], [12]. All these discoveries realized at the end
of the nineteenth century, made clear that chemical exposure was in part the cause of a number
of types of cancer and that even occupational exposure was correlated with specific types of
cancer. These findings suggested that certain chemical species that come in contact with the
human body could perturb tissues and cells and ultimately induce the emergence of a tumor.
Since then, it was also thought that chemical species present naturally in foodstuffs or generated
during cooking could also induce cancer. It was not until the 1960’s when William Lijinsky
decided to test this by broiling steaks in charcoal, ultimately finding 8 micrograms of
benzo[a]pyrene per kilogram of broiled steak [12]. Linjisky continued his research on processed
food finding other sorts of carcinogens such as nitrosamides, nitrosamines, and nitrites.
Since 1761, it was determined that certain chemicals were carcinogens, however, the
biological explanation for these incidents was unknown until studies in the field of genetics
initiated. In 1927, the geneticist Hermann Joseph Muller discovered that exposure of Drosophila
melanogaster to X-rays induced mutations in the DNA of the flies’ cells [13]. This event led
Muller to carry out studies on the mechanisms of the gene mutation, thus being able to explain
how genes rearranged.
Further epidemiologic correlations made in 1949 and 1950, among smokers and
nonsmokers, gave the most compelling association between environmental exposure and cancer
incidence. Two groups of epidemiologists reported that individuals who were heavy cigarette
smokers were more than twenty times in risk of developing lung cancer than nonsmokers [14],
[15]. These findings proved to be critical for subsequent cancer research, since they suggested
that cancers often had specific, assignable causes. Indeed, in reports from 1950-2000,
epidemiologists identified a variety of environmental and lifestyle factors that were strongly
correlated with the incidence of certain cancers; in some of these cases, researchers have been
able to discover the specific biological mechanisms through which these factors act to cause
4

increased incidence of some of these cancers. In order to study the biological reasons for cancer
initiation and development, researchers decided to recreate cancer in the laboratory. Thus,
cancerous cell lines were established by treating laboratory animals with various carcinogens
found in coal tar and petroleum products [16]. Tumors were isolated from the animals and grown
in vitro in supplemented media. An extensive assortment of cancerous cell lines have also been
established from tumors removed from patients. Some of these cell lines are still in use today to
study mechanisms of cellular death resistance and for testing chemotherapeutic drugs. It is from
these tumor cell lines that we have gained most of our contemporary knowledge of cancer.
Another independent line of research surged during the first decade of the twentieth
century to find explanation for the initiation of cancer. These scientists hypothesized that not
only chemicals or lifestyles were responsible of cancer, but other agents influenced initiation of
cancer as well. Francis Peyton Rous, a pathologist, was one of the pioneers who in 1910
discovered a virus to be a tumor causing agent [17]. A farmer brought him a chicken with a lump
in the chest. He removed the tumor and identified it as a sarcoma tumor type that was growing
on the chicken. He cleaned the tumor from other cells, minced, and filtered the disrupted cells in
saline solution, the isolated filtrate (free from bacteria and cancerous cells) was transferred to
another healthy chicken and later the animal developed a tumor. He removed the tumor from this
other chicken and repeated the same experiment in other healthy chicken. He repeated this many
times discovering that the tumor was more aggressive each time. He concluded that an infectious
agent was responsible for the tumors. At this time viruses were not well understood and the
causes of cancer were not completely elucidated. Twenty years later, Richard Shope, a colleague
of Rous, discovered the papilloma virus in rabbit’s warts [18]. It was confirmed that the
Papillomavirus (HPV) was responsible of warts. Rous returned to his experiments and was able
to isolate the Rous sarcoma virus (RSV) confirming and concluding this was the etiologic agent
of sarcoma. After this, a wide variety of viruses able to induce cancer were found. For example,
various DNA (i.e. Hepatitis B virus, adenovirus, and herpesvirus) and RNA (i.e. Human T-cell
5

Leukemia Virus) tumor viruses were discovered. Even a virus with the ability to induce a variety
of distinct tumor types was discovered in 1953, and was named Polyomavirus [19].
Viruses are generally simple in structure, composed of nucleic acid (DNA or RNA)
wrapped in a protein coat (a capsid) and, in some cases, a lipid membrane surrounds the capsid.
When isolated, viruses are metabolically inert. They can multiply only by infecting and
parasitizing a suitable host cell. The viral genome, once introduced into the cell, provides the
instructions for the synthesis of progeny virus particles. The host cell provides the machinery
required for viral replication and transcription. The endpoint of the replication cycle is the
production of hundreds, even thousands of progeny virus particles that can then leave the
infected cell and proceed to infect other susceptible cells. The way viruses cause tumors is by
activation or addition of oncogene copies into the host genome. Viruses can be carriers of
oncogenes that were part of a previous host’s genome or can insert into the vicinity of a cellular
oncogene functioning as a positive transcriptional regulator and thus activating the tumorigenic
potential of the cellular gene [20]. This is typically a slow process and requires prolonged and
extensive viral replication and integration. In the same way, viruses can affect the proper
expression of tumor suppressor genes by inserting and interfering with original DNA sequences
[21].
About one-fifth of deaths from cancer worldwide are associated in one way or other with
infectious agents [22]. Fifty to seventy-five percent (50-75%) of stomach cancer mortality
worldwide is attributable to long-term infections with Helicobacter pylori (H. pylori), fifty to
seventy percent (50-70%) of hepatocellular carcinoma cases worldwide are associated with
chronic hepatitis B and C virus infections, and Human Papilloma Virus has been implicated in
99.7% of cervical squamous cell cancer cases worldwide [23], [24], [25]. Cancer can be
portrayed as an environmental and/or infectious disease, since the evidence gathered from cancer
research asserts that physical, chemical, environmental agents, bacteria, and viruses are causative
agents of cancer.
6

A more concrete example on the dependence of cells on their surrounding is in the case
of stomach and intestinal cells in direct contact with normal flora and pathogens. As previously
mentioned, H. pylori, is considered the most common etiologic agent of infection-related
cancers. In some individuals, H. pylori colonization does not cause any symptoms, but long-term
carriage of H. pylori significantly increases the risk of developing gastric cancer. Among
infected individuals, approximately 10% develop peptic ulcer disease, and of those 1 to 3%
develop gastric adenocarcinoma, and <0.1% develop mucosa-associated lymphoid tissue
(MALT) lymphoma [26]. How exactly H. pylori causes gastric cancer is by the expression of
cytotoxin-associated gene A (CagA) protein that leads to gastric epithelial cell proliferation and
carcinoma via the Wnt signaling pathway [26], [27].
The close relationship and dependence of cells on their surroundings have been
demonstrated experimentally. This is has been nicely illustrated by the behavior of normal cells
[26]when they are removed from living tissues and propagated in vitro. Even though the liquid
medium used to culture normal cells contains all the nutrients required to sustain their growth
and division, including amino acids, vitamins, glucose, and salts, such medium, on its own, it
does not support the proliferation of normal cells. Instead, cell proliferation depends upon the
addition of serum to the medium, usually prepared from the blood of calves or fetal calves [28].
This serum contains the growth factors that promote cellular proliferation. Growth factors, such
as cytokines and hormones, convey many of the signals that tie the cells within a tissue together
into a single community, all members of which are in continuous communication with their
neighbors. Thus, agents surrounding the cells are important to consider as etiologic factors in
cancer development.
1.3

DNA repair mechanisms during genomic and epigenomic alterations
Non-cancerous mammalian cells contain well-organized chromosomes which in

metaphase visibly consist of two sister chromatids attached at the centromere. The number, sizes,
and shapes of the metaphase chromosomes are particular to each pair. In contrast, cancerous cells
7

exhibit aberrantly structured chromosomes of various sorts (Fig.1.4) [6]. These mutated cells can
contain extra copies of chromosomes; can show the loss of entire chromosomes, and the fusion
of the arm of one chromosome with another [29]. These changes in chromosomal configuration
directly contribute to genetic instability and to the alteration of gene expression [30]. All these
sorts of mutations arise and kept on cancerous cells as consequence of inefficient gene regulation
and repair mechanisms.
The chromosomes of healthy cells may undergo changes in their structure, but these
changes are detected, reverted, and repaired. Endogenous and exogenous events can inflict
damage to the cell's genome and can severely compromise its integrity [31]. Thus, to counteract
these damaging effects and maintain the genomic integrity, three major conserved cellular
pathways have evolved [32]. One is the DNA damage response, which ensures efficient repair
of all types of damage. DNA damage can include different sorts of translocations and inversions.
Chromosomal translocations result when DNA segments from one chromosomal arm and
become fused to the arm of another chromosome [33]. There is another type of chromosomal
translocation termed reciprocal translocation that results when chromosomal segments are
exchanged between different chromosome pairs and each chromosome receives a segment. A
chromosomal segment may also become inverted, which may affect the regulation of genes that
are located near the breakage-and-fusion points. The second pathway to correct DNA damage is
the chromosome replication pathway which accurately governs the replication of DNA. Single
base-pair substitutions, for example, can occur during DNA replication. A well-structured
chromosome replication pathway is so essential because only a point mutation in the DNA
sequence of a proto-oncogene is all that is required to convert a normal gene into a potent
oncogene [34]. Point mutations can affect the structure of proto-oncogene-encoded proteins too,
converting them into active oncoproteins. Cellular receptors (which are made of protein) once
mutated can be potent causative agents of cancer. Amplification and overexpression of receptor
genes can be accomplished also by the insertion of oncogenes or virus in the promoter region of
8

the gene. In other instances, these receptors are always “ON” continuously transmitting signals
for cell division even in the absence of growth factors that turn “ON” the growth receptors. As an
important example, there is the epidermal growth factor receptor (EGF-R) that extends from the
extracellular space through the plasma membrane of cells into the cytoplasm. Normally, EGF-R,
like almost all other 60 similarly structured receptors, in resting state is in an auto-inhibitory
conformation and its kinase domain in the inactive form. Presence of its cognate ligand (i.e.,
EGF protein) in the extracellular space induces receptor mediated dimerization that brings the
intracellular domains into close proximity, promoting the association of kinase domains and a
signaling cascade is activated in the cell interior [35]. In response to these signals, a gene is
transcribed for the production of more EGF proteins for cellular growth. The catalytic activity of
EGFR is tightly regulated in normal cells by protein-tyrosine phosphatases, by other protein
tyrosine or serine/threonine kinases, and by autoregulatory mechanisms [36]. When the EGFR
gene contains point mutations at exons 19 and 21 the coded EGF protein behaves in a different
way.

These EGFR mutations affect the resting state conformation of the receptor causing

receptor dimerization and the auto-activation of the EGFR pathway promoting EGFR-mediated
pro-survival signals to downstream targets [37]. The third pathway to correct DNA, is the
chromosome segregation pathway which preserves the correct number of chromosomes during
cell division. There are occasions in which also the produced DNA copies may be fused head-totail forming a chromosomal segment that is termed homogeneously staining region (HSR). A
DNA segment may also be cleaved out of a chromosome, replicated as an autonomous extra
chromosomal entity, and increase to many copies per nucleus, resulting in the appearance of sub
chromosomal fragments termed double minutes (DMs). These latter two changes cause increases
in the copy number of genes carried in such segments, resulting in gene amplification [38].
Sometimes, both types of amplification can coexist in the same cell and independently favor the
growth of cells by increasing the copy number of growth-promoting genes. All this three cellular
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pathways exhibit crosstalk, forming a network in which disruption of one pathway leads to
engagement of the others to protect genome integrity while maintaining cell homeostasis.
Further genomic alterations of DNA leading to cancer consist also on the elimination of
growth-inhibiting genes (tumor suppressor genes). These can be accomplished by deletions and
methylations. When a segment in the middle of a chromosomal arm is discarded and the flanking
chromosomal regions are joined, this results in an interstitial deletion (Fig.1.4). Thus, deletions
cause incomplete or multiple coding sequences for protein synthesis consequently altering
cellular function. This is exemplified by retinoblastomas (RBs), which mRNA transcripts are
either markedly reduced in quantity or are abnormal in length. About 40% of RBs are caused by
DNA deletions and accordingly affect mRNA transcript [39]. Thus, absence or non-biological
functional RB protein leads to cancer.
Additional alterations in gene expression include epigenetic modifications. These are
stable alterations in gene expression that takes place during cell proliferation and occur without
causing changes in gene sequence. DNA methylations constitute the most commonly occurring
epigenetic modification and are also involved in cancer development [40]. DNA methylations
are covalent chemical modifications, resulting in the addition of a methyl (CH3) group at the 5’
carbon of the cytosine ring. Methylations in DNA prevent the binding of polymerases for DNA
transcription leading to gene silencing. In cancer, tumor suppressor genes are often
hypermethylated leading to cell proliferation and ultimately cancer. Tumor suppressor genes are
known to be antigrowth genes. Tumor formation seemed to happen when these genes are
inactivated by methylations or are deleted. Another recognized cause of oncogenesis is
hypomethylation.

This

epigenetic

abnormality,

discovered

in

1983

and

prior

to

hypermethylation, frequently occur in highly repeated DNA sequences [41]. Hypomethylation of
transcription regulatory regions seems to be less frequent than hypermethylation of DNA
promoter regions [42], [43]. Nonetheless, hypomethylations frequently take place in transcription
control sequences, including heterochromatic DNA repeats, dispersed retro-transposons, and
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endogenous retroviral elements [44], [45]. Hypomethylations of these regions may cause a
gene’s constant expression which can lead to cell proliferation and eventually cancer.
1.4

Tumor suppressor genes and the immune system are allies in getting rid of cancer
As discussed in the previous section, mammalian cells count with an elaborate cellular

repair apparatus that continuously monitors the genome integrity and replaces mutant sequences
of DNA with appropriate wild-type sequences.

This repair apparatus maintains genomic

integrity by minimizing the number of mutations that strike the genome of a particular cell [46].
Conversely, no system is infallible and some mistakes in genetic sequences can survive its
scrutiny. Genome mistakes can become fixed in a particular cell at a particular time; nonetheless,
prior to the repair, mutations can be copied into newly synthesized DNA molecules, and passed
on as mutations to progeny cells. In this sense, many of the mutations that accumulate in the
genome represent the consequences of occasional oversights made by the repair apparatus. Yet
other mistakes are the results of significant damage to the genome that exceeds the capacities of
the repair apparatus. Fortunately, there are other systems to get rid of cancer. These systems are
the immune system and tumor suppressor genes that can work together to control cancer [47].
Evidence about the immune system’s contribution in the elimination of cancerous cells
has been rapidly accumulating. Thus, three fundamental roles of the immune system against
cancer have been recognized and these are the following: (1) protection against pathogens that
induce tumors, (2) elimination of inflammation, and (3). elimination of certain cancerous cells
[48]. Not all cancerous cells or all pathogens are eliminated by the immune system, because
these employ various strategies to evade detection and elimination. This in turn is aggravated by
difficulties associated with the immune system’s organization in recognizing what is self and
what is strange or not-self [49]. However, there are features of cancerous cells that distinguish
them apart from normal cells [50]. Tumors differ fundamentally from normal cells in antigenic
composition and biologic behavior. Thus, they have multiple genetic alterations, epigenetic
instability, and abnormal expression of growth factors that induce altered density in antigen
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levels, inflammation, and ultimately invasion and metastasis.

Some of these differences

significantly impact the interaction between cancerous cells and the immune system perhaps
representing a frailty of cancer, which can be exploited therapeutically.
Under these circumstances, immunological cells, such as Natural killer (NK) cells are
able to recognize and kill cancerous cells that do not display normal levels of surface molecules
like Major Histocompatibility Complex (MHC) I [51]. Once NK cells identify cancerous cells as
targets for elimination, they release IFN-γ in the vicinity of the targeted cells. Released IFN-γ, in
turn, elicits several distinct responses [52]. IFN-γ enables the NK cells to call in other types of
immune cells to assist in killing targeted cancerous cells, thereby amplifying the immune
system's response.
Another, line of evidence supporting the role of the immune system in protecting against
cancer is the relationship between immunity and tumor suppressor genes. As an example, there is
the tumor suppressor p53, which is well-known for its role in regulating apoptosis and the cell
cycle, therefore maintaining the stability of the genome. In recent years, p53 has been
adjudicated with additional biological functions including autophagy, fertility, nutritional
responses, cell motility/migration, cell-cell communication, and regulation of the human immune
system [53]. The expression of p53 upon DNA damage can trigger clearance of damaged cells or
tumors via the innate immune system, as evidenced by in vitro and in vivo experiments [54].
Thus, the mechanism for this is still unknown, though believed to occur through NKG2D (Killer
cell lectin-like receptor subfamily K, member 1 or CD314) system and up regulation of ULBP2
(NKG2D ligand 2) [55].
1.5

Past and present cancer statistics
In 2008, it was estimated that about 1,437,180 new cancer cases of the top ten cancer

types were expected to be diagnosed, and about 565,650 people in the US were projected to die
of cancer (SEER statistics, 2008). In 2014, it is estimated that in the US there will be 1,665,540
new cases of the top ten cancer types and an estimated 585,720 people will die of these diseases
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(Table1.1). Thus, there are 228,360 more expected cases and 20,070 more deaths for 2014 than
in 2008. In Table 1.1 are shown the most common cancer types in the US and these are prostate,
breast, lung, colon, melanoma, bladder, lymphoma, kidney, thyroid, and endometrial cancer.
Among these, melanoma and thyroid cancer incidences and deaths account for the rise in cancer
incidences and deaths for 2014.
Despite efforts in education, prevention, screenings, and investment on cancer research,
statistics are telling us that cancer burden in the US is on the increase. In the US, cancer remains
the second most common cause of death, accounting for nearly 1 of every 4 deaths since 2008
statistics (American Cancer Society, 2013). In comparison to the cancer estimates in 1991, an
actual estimate has been reduced by about a 20% [56]. This short-lived declining trend could be
in part attributed to disadvantages in anticancer therapies, population aging, lifestyle risk factors,
(tobacco use, diet, obesity, lack of exercise, alcohol consumption, and excessive exposure to
sunlight), environmental and occupational exposures to carcinogens and mutagens, (including
chemicals and radiation), infectious agents (Helicobacter pylori, hepatitis B virus, hepatitis C
virus, human papillomavirus, and Epstein-Barr virus), chronic inflammation, hormone
metabolism, family history, ethnicity, and socioeconomic status [57]. Disadvantages of
anticancer therapies include poor selectivity and resistance development having major concerns
in poor prognosis [58]. Anticancer drugs with poor selectivity toward cancerous cells lead to
toxicity and life-threatening negative side effects. Resistance to anticancer drugs originates from
diverse genetic alterations evolved on cancerous cells. Therefore, significant reduction in the
rates of cancer incidence and mortality requires further global education, lifestyle changes,
collaborations among different institutions, and research on prevention, detection and treatment.
1.6

Advances in therapeutic treatments and cancer prevention
Improvements in anticancer therapies have been made possible by successfully

combining different traditional therapeutic approaches and by discovering novel therapies.
Traditional therapeutic approaches against cancer comprise radiation therapy, surgery, and
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chemotherapy [59]. Development of vaccines, combined chemotherapies, and antibodies has
been also improving outcomes among certain cancer types. Even more advances in techniques
such as magnetic resonance imaging, ultrasonography, immunohistochemistry, and flow
cytometry are offering early cancer detection and diagnosis. In addition, there is a growing
amount of preventive strategies against cancer based on the discovery of phytochemicals in
vegetables, fruits, roots and leaves and outcomes from the performance of physical exercise have
also been identified.
The intense scientific studies on the properties of vegetables, fruits, roots, and leaves
against cancer initiated around the 1990’s [60]. Plant derived products offer antioxidants that act
by avoiding oxidative damage of the cell and supporting the immune system [61], [62]. In
addition to the benefits from nutrition, studies have shown the positive impact of moderate
physical exercises as well for the prevention and survivorship of cancer. Exercise promotes
reduced levels of insulin, glucose, sex hormones, and inflammation, and increases intestinal
motility and immune system response [63], [64]. Nutritional and exercise strategies to fight
cancer should be seriously implemented in our daily routines. In 2014 the World Health
Organization (WHO) alerted about a global cancer surge fuelled by alcohol, smoking and obesity
projecting a 70% of increase in cancer cases by 2032.
Indeed, novel anticancer drugs and more effective treatments are needed. Although the
pharmaceutical industry will undoubtedly continue to develop new therapies against cancer, a
contribution from the academic sector to the early drug discovery phases can guarantee the rapid
identification of targets [65]. Industry alone cannot support the required breadth of drug
discovery efforts, thus only by association with academic institutions can this be accomplished.
With the purpose of contributing to anticancer drug discovery, we have evaluated the in vitro
potential of hundreds of compounds developed by Dr. Jonathan R. Dimmock, Dr. Umashankar
Das, Dr. Swagatika Das, and other collaborators. We have discovered that the most cytotoxic
compounds among the library to be curcumin-like molecules with novel functional groups that
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displayed greater toxicity to leukemia and lymphoma cells than to control non-malignant
MCF10A and Hs-27 cell lines. These molecules were also found to exhibit little if any toxicity to
other types of cancer cell lines such as those derived from breast, colon, and prostate cancers
1.7

Curcumin and its analogues against cancer
Discoveries of plant-based drugs with the ability of influencing multiple targets and

showing reduced normal cell toxicity are desired. These effects may diminish therapy
disadvantages and improve patient prognosis. In addition, drugs that are able to induce cancerous
cell death at low micromolar concentrations, via apoptosis, and without disturbing normal cells
have therapeutic advantages and thus are preferred [66]. These properties reduce drug dose,
normal tissue toxicity, and inflammation.
From the dried roots of the Curcuma longa (turmeric) plant, we can obtain a class of
compounds known as the curcuminoids, comprised of curcumin, demethoxycurcumin,
bisdemethoxycurcumin, and cyclocurcumin [67]. Curcuminoids consist of two methoxylated
phenols connected by two α, β unsaturated carbonyl groups. Curcumin is naturally available in
turmeric as two chemical conformations the keto and enol with the enol conformation being
more stable. Curcumin is the principal curcuminoid and comprises approximately 2-5% of
turmeric. It is responsible for the yellow color of the spice as well as the majority of turmeric’s
therapeutic effects.
For years, curcumin has been an attractive natural therapeutic agent. Its value prevails on
the interaction and regulation of multiple cellular targets, the ability to modulate growth and
transcription factors’ expression and activity, induction in the production of inflammatory
cytokines, down-regulation of enzymes, and apoptosis induction without affecting non-cancerous
cells. Preclinical and clinical trials have revealed that high doses of curcumin are non-toxic to
humans or animals. However, phase I clinical trials have shown that curcumin failed as therapy
due to its low bioavailability after its digestion [68]. Synthetic modifications to curcumin’s
molecule or the synthesis of analogues may overcome curcumin’s deficiencies as a therapeutic
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drug by making a molecule more potent and difficult to metabolize [69]. One of the major
problems with curcumin is its low bioavailability in vivo [70]. The degradation kinetics and the
stability of curcumin under various pH conditions were examined by Wang et al. [71]. Their
results show that about 90% of curcumin was decomposed within 30 minutes when incubated in
0.1 M phosphate buffer and serum-free medium, pH 7.2, at 37ºC. A series of pH conditions
ranging from 3 to 10 were tested and the result showed that decomposition was pH dependent
and occurred faster at neutral-basic conditions. Thus, it was found that curcumin is more stable
in cell culture medium containing 10% fetal calf serum and in human blood. Under these
conditions less than 20% of curcumin decomposed within 1 hr and, after incubation for 8 hrs,
about 50% of curcumin still remained. The reasons for curcumin’s reduced bioavailability are
poor absorption and rapid metabolism severely diminishing its bioavailability as revealed by
studies over the past decades [72]. To overcome the aforementioned conditions curcumin
analogues have been developed.
The need for curcumin-like compounds with improved bioavailability has led to the
chemical synthesis of a series of analogues, using curcumin as the lead structure. One such
compound is EF-24, a synthetic curcumin analogue that showed cell cycle arrest and apoptosis
by a redox-dependent mechanism in MDA-MB-231 human breast cancer cells and DU-145
human prostate cancer cells [73]. However the effect of EF-24 on lymphoid cancerous cell lines
is more necrotic than apoptotic within 24 hrs of incubation. The curcumin analogues that we
have characterized are more apoptotic than EF-24 (Fig. 1.5). Although, EF-24 is more
bioavailable than curcumin [74], it shows more in vitro toxicity to normal peripheral blood
mononuclear cells (PBMC’s). The same effect has been observed with other curcumin analogues
(Fig. 1.6). Thus, in vivo experiments on EF-24 or other analogues derived from curcumin show
no cytotoxicity in animals [19], [20].
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So far, we have characterized the cell death of interesting curcumin-like analogues able to
induce significant cytotoxicity at low micromolar concentrations. They do kill cancerous cells
through apoptosis and present selectivity for leukemia and lymphoma cells over other types of
cancerous and normal cells. The following two chapters will present data on the relationship
between structure and activity of 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimmers against
leukemia and lymphoma and on a novel curcumin analogue which sensitizes leukemia and
lymphoma cells to apoptosis by induction of TNF-α and DAPK1.

Figure 1.1: Hypothetical model of the stages in tumor development.
A. The tumor begins to develop when a cell experiences an uncorrected mutation. B. The
altered cell divides too often (hyperplasia) passing the mutation on to its progeny during cell
growth and division. At some point, one of these cells experiences another mutation that further
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increases its tendency to divide, thus looking abnormal in appearance (dysplasia). C. If the tumor
that has formed from these cells is still contained within its tissue of origin, it is called in situ
cancer. In situ cancer may remain contained indefinitely. D. If some cells experience additional
mutations and recruit stromal cells (i.e. pericytes or endothelial cells) that allow the tumor to
invade neighboring tissues and shed cells into the blood or lymph, the tumor is said to be
malignant. The escaped cells may establish new tumors (metastases) at other locations in the
body.

Figure 1.2: DNA composition.
DNA is composed of four different nitrogenous bases bonded to a sugar-phosphate
backbone. Thus, bases can be classified into pyrimidines (thymine and cytosine) and purines
(adenine and guanine). The nucleotides are covalently linked together in a chain through the
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sugars and phosphates, which thus form a “backbone” of alternating sugar-phosphate-sugarphosphate. Hydrogen bonds between the base portions of the nucleotides hold the two chains
together. The three-dimensional structure of DNA, the double helix, arises from the chemical and
structural features of its two polynucleotide chains.

Figure 1.3: From DNA to protein.
Signals from the outside can stimulate cell membrane receptors to trigger cell division or
protein synthesis. During cell division, both strands of DNA are replicated and passed to
daughter cells. During protein synthesis, one of the strands is transcribed into pre-messenger
RNA. Coding and noncoding regions of DNA are transcribed into pre-mRNA. Some regions are
removed (introns) during initial mRNA processing. The remaining exons are then spliced
together, and the spliced mRNA molecule (red) is prepared for export out of the nucleus through
addition of an endcap (green sphere) and a polyA tail. Once in the cytoplasm, the mRNA can be
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used to construct a protein. From this Central Dogma of Molecular Biology, it was determined
that mutated DNA induces mutated proteins and malfunction of the cell, thus conducing to
pathologies.

Figure 1.4: Hypothetical karyotype in cancer.
In humans, each cell normally contains 23 pairs of chromosomes, for a total of 46. The
number, sizes, and shapes of the chromosomes are particular to each pair. In contrast, when there
is extra or missing chromosome material, pathology is suspected. Thus, chromosome imbalances
may occur because of a change in the number or structure of the chromosomes. Usually,
differences in the amount of chromosome material can affect an individual’s growth and
development and may cause birth defects and/or mental retardation. In addition, an individual
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with aberrantly structured chromosomes of various sorts can present cancer. The arrows indicate
aberrant chromosomes with deletions or insertions.

Table 1.1: Number of new cancer cases and deaths (2014)
Estimated New

Estimated Deaths

Common Types of Cancer
Cases 2014

2014

Prostate Cancer

233,000

29,480

Breast Cancer (Female)

232,670

40,000

Lung & Bronchus Cancer

224,210

159,260

Colon & Rectum Cancer

136,830

50,310

Melanoma of the Skin

76,100

9,710

Bladder Cancer

74,690

15,580

Non-Hodgkin Lymphoma

70,800

18,990

Kidney and Renal Pelvis Cancer

63,920

1,820

Thyroid Cancer

62,980

1,890

Endometrial Cancer

52,630

8,590

-

-

-

All Cancer Sites

1,665,540

585,720

Source: SEER 2014 Cancer Statistics Factsheets: All Cancer Sites. National Cancer
Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/all.html
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Figure 1.5: Apoptosis induction of curcumin analogues compared to curcumin.
When tested at 1µM for 24 hrs curcumin is not effective killing lymphoid cancerous
cells. Its analogues EF-24 and an analogue synthesized by Dr. J.R.Dimmock (University of
Saskatchewan) show more cytotoxic potential. The analogue synthesized by the group in
Saskatchewan show more apoptotic capabilities than EF-24, a known curcumin analogue in
clinical trial.
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Figure 1.6: Toxicity of curcumin analogues on normal lymphocytes.
When tested at 1µM for 24 hrs curcumin shows not toxicity on normal peripheral blood
mononuclear cells (PBMC’s). However, its analogues EF-24 and an analogue synthesized by Dr.
J.R.Dimmock (University of Saskatchewan) induce toxicity to the cells.
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Chapter 2: Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: Structureactivity relationships and potent antileukemic and antilymphoma
cytotoxicity
Novel clusters of 3,5-bis(benzylidene)-4-oxo-1-piperidinyl dimers 3e5 were evaluated
against human Molt4/C8 and CEM T-lymphocytes and human HeLa cervix adenocarcinoma
cells as well as murine L1210 leukemia neoplasms. Several of these compounds demonstrated
IC50 values in the submicromolar and low micromolar range and compounds possessing 4fluoro, 4-chloro and 3,4,5-trimethoxy substituents in the series 3 and 4 were identified as potent
molecules. A heat map revealed the very high cytotoxic potencies of representative compounds
against a number of additional leukemic and lymphoma cell lines and displayed greater toxicity
to these cells than nonmalignant MCF10A and Hs-27 neoplasms. These dienones are more
refractory to breast and prostate cancers. The evaluation of representative compounds in series
3e5 against a panel of human cancer cell lines revealed them to be potent cytotoxins with
average IC50 values ranging from 0.05 to 8.51 mM. In particular, the most potent compound 4g
demonstrated over 382-fold and 590-fold greater average cytotoxic potencies in this screen than
the reference drugs, melphalan and 5-fluorouracil, respectively. A mode of action investigation
of two representative compounds 3f and 4f indicated that they induce apoptosis which is due, at
least in part, to the activation of caspase-3 and depolarization of the mitochondrial membrane
potential.
2.1

Introduction
The principal interest in our laboratories is the design, synthesis and antineoplastic

evaluation of conjugated unsaturated ketones. The perceived importance of these compounds is
their ability to interact preferentially with thiols in contrast to amino and hydroxyl groups [75],
[76] which are present in nucleic acids. Thus the genotoxic properties displayed by various
alkylating agents in cancer chemotherapy [77] may well be absent in conjugated enones. Initially
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compounds containing one a,b-unsaturated group were prepared which demonstrated cytotoxic
and anticancer properties [78]. However, a number of studies showed that an initial chemical
insult followed by a second interaction with cellular constituents can be more harmful to tumors
than nonmalignant cells [79], [80], [81]. Hence an additional conjugated enone group was
introduced into the design of candidate cytotoxins leading to the mounting of the 1,5-diaryl-3oxo-1,4-pentadienyl pharmacophore onto a number of heterocyclic and carbocyclic scaffolds
such as series 1 as indicated in Fig. 2.1. In these compounds the capacity for sequential
alkylation of cellular thiols now exists.
In recent years a novel cluster of cytotoxic agents were developed possessing two 1,5diaryl-3-oxo-1,4-pentadienyl groups which have the general structure 2 as indicated in Fig. 2.1.
In this way multiple sequential alkylations of cellular thiols can take place. Most of the
compounds displayed micromolar or submicromolar IC50 and CC50 values against various
neoplastic cell lines [82], [83]. In general, the greatest potencies were found in those compounds
with the shortest linker group X between the two piperidinyl nitrogen atoms. From these studies,
two compounds possessing oxalyl and malonyl linkers were identified as the most promising
cytotoxic agents and are referred to as 3a and 4a, respectively. An initial study examined the
compounds in series 3-5, against HCT116 and HT29 human colon cancer cells [84]. In general,
these compounds are potent cytotoxins having IC50 values less than 1 µM in 78% of the
bioassays and are substantially more potent than 5-fluorouracil which is used clinically in
treating colon cancers. These encouraging results justify the further bioevaluation of series 3-5.
The next phase of the study was threefold. 1. An examination of the effects of placing
different substituents into the aryl rings of 3a and 4a on cytotoxic potencies was proposed. The
variations in the electronic, hydrophobic and steric properties of the aryl substituents may enable
correlations between these physicochemical properties and cytotoxic potencies to be established.
The groups chosen had either positive (+) or negative (-) Hammett σ and Hansch π values
namely 4-fluoro, 4-chloro and 3,4-dichloro (+,+), 4-methyl and 4-dimethylamino (-,+) and 3,425

dimethoxy, 3,4,5-trimethoxy and 4-methoxy (-,-). In addition, there are substantial differences in
the sizes of the aryl groups. For example, the molar refractivity (MR) values of the 4-fluoro and
3,4,5-trimethoxy groups are 0.92 and 23.61, respectively [85]. 2. The aspiration was made to
gain some idea of the sensitivity of these compounds towards human lymphomas and leukemia
cancers and if tumor selectivity compared to normal cells was demonstrated. 3. An investigation
was planned to find some of the ways in which promising lead compounds exert their
antineoplastic effects.
The overall objective is that these investigations will enable one or more promising
prototypic cytotoxic molecules to be identified which will be developed from the prospective of
their drug-likeness properties [86] (see Fig. 2.2).
2.2

Results
The syntheses of 3a and 4a has been described previously [82] and a literature method

was used for the preparation of 3b-i, 4b-i and 5 [84]. In brief, various aryl aldehydes were
condensed with 4-piperidone to produce the corresponding 3,5 bis(benzylidene)-4-piperidones.
Acylation of these dienones with oxalyl or malonyl chlorides gave rise to series 3 and 4,
respectively. Reaction of 3,5-bis(benzylidene)-4-piperidone with 1,3-dibromopropane led to the
synthesis of 5.
The dienones 3aei, 4aeh and 5 were evaluated against human Molt4/C8 and CEM Tlymphocytes, human cervix carcinoma HeLa cells and murine L1210 leukemic cells. These
results are presented in Table 1. The results of the cytotoxic evaluation of 3b, c, e-h, 4b, c, e, f
and 5 against a number of lymphomas as well as breast and prostate cancer cell lines are
presented as a heat map in Fig. 2.3 while a summary of these bioevaluations is portrayed in
Appendix Tables S1 and S2. In addition, 3a-d, g, 4a, c, e, g, i, and 5 were evaluated against a
panel of human cancer cell lines including human colon cancer and leukemic cell lines and these
results are summarized in Table 2.2.
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The modes of action of the dienones 3f and 4f in CEM cells were also investigated. Both
compounds induce cell death via apoptosis, activate caspase-3 and depolarize the mitochondrial
membrane potential. These results are presented in Figs. 4-6, respectively.
2.3

Discussion
The dienones 3a-i, 4aeh and 5 were evaluated against non-adherent Molt4/C8 and CEM

T-lymphocytes as well as adherent HeLa adenocarcinoma cells with a view to determine if the
compounds displayed efficacy towards human transformed and neoplastic cells. In addition,
compounds which are cytotoxic to non-adherent cells may have the potential to inhibit the
growth of tumors with metastatic potential. The murine L1210 assay was employed as a number
of anticancer drugs are toxic to this cell line [87] and hence this bioassay may point to
compounds with clinical utility.
The biodata presented in Table 1 reveals that the majority of the compounds are potent
cytotoxins. No less than 39% of the IC50 values are submicromolar and in particular the IC50
figures of 3b, c, g and 4f, g are submicromolar in all four bioassays. In the case of 3b, g and 4a,
g, the IC50 values in the Molt4/C8 screen are in the double digit nanomolar range (10 -8 M) and
are clearly lead molecules. Furthermore, the relative cytotoxic potencies of the compounds in
series 3 and 4 were verified against the four neoplastic cell lines using Kendall’s coefficient of
concordance [88]. This nonparametric test is based on ranks and ignores the magnitude of the
differences in the potencies of groups of compounds. The derivation of the equation used in these
determinations is given in the Appendix Section. The relative potencies of 3a-i are the same in
the Molt4/C8, CEM, HeLa and L1210 bioassays since Kendall’s coefficient of concordance is
0.9812 (p =0.0001). A similar situation prevails among the analogs 4a-h; in this case, Kendall’s
coefficient is 0.9315 (p = 0.0005). Furthermore, when all of the dienones in series 3 and 4 are
considered, the relative potencies are the same as revealed by Kendall’s coefficient of 0.9504 (p
< 0.0001). Thus it is likely that these alkylating agents which are designed to target thiol
macromolecules e.g., glutathione, cysteine, thioredoxin reductases and glutathione S-transferase
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isozymes appear to act with the same molecular targets in all four cancer cell lines. The
variations in potencies include differences in the alignment of the compounds at their binding
sites.
In order to make some specific observations regarding the effects of placing different
substituents in the aryl rings on cytotoxic potencies, the average IC50 values in the four
bioassays presented in Table 1 were computed. Both 3c and 4c possess a para chloro group and
display excellent potencies; however the addition of a metachloro atom leading to 3d and 4d
brings about 45- and 38-fold decreases, respectively, in the average IC50 values. Very
interestingly, the replacement of a para chloro group in 3c and 4c by a methoxy group led to 3h
and 4h, respectively that were virtually inactive. On the other hand, the addition of a meta
methoxy group to 3h and 4h leading to 3f and 4f increased potencies by 25- and >1038-fold,
respectively. Still greater increases in potencies were noted with the 3, 4, 5-trimethoxy analogs
3g and 4g whose average potencies are the highest among the compounds in series 3-5. The
replacement of a chloro group in 3c by a fluoro group (3b) in series 3, lead to an increase in the
average cytotoxic potency by over 2-fold. The relative cytotoxic potencies of the compounds in
series 3 and 4 which have different para substituents are F > Cl > H > CH3 > OCH3 and H > Cl >
CH3 >F > OCH3, respectively. This observation reveals that in addition to the electronic,
hydrophobic, and steric properties of the aryl substituents, the nature of the linker groups
between the piperidinyl nitrogen atoms influences the magnitude of the IC50 values. This point
is further illustrated in comparing the biodata between 4a and 5. Compound 5 which possesses
no carboxamide group is 5-fold less potent than 4a, suggesting that the two carbonyl groups in
carboxamide group present in 4a contribute to the cytotoxic potencies observed. Linear and
semilogarithmic plots between the σ, π, and MR constants of the aryl substituents in series 3 and
4 and the IC50 values generated in each of the four bioassays were undertaken. However no
correlations (p < 0.05) or trends toward a correlation (p < 0.1) were noted. The mean of the
average potencies of 3a-h and 4a-h are 16.9 and >53.8 µM, respectively, revealing that
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compounds in series 3 are more potent than the series 4. If the data for the two outliers 3h and 4h
are discounted, the relevant figures are 5.39 and 6.66 µM, respectively. Hence the oxalyl linker
in series 3 is marginally preferred in terms of potency.
Comparisons were made between the cytotoxic properties of the compounds in series 3-5
and two reference compounds, melphalan and curcumin. Melphalan is an alkylating agent used
in cancer treatment, while there is considerable interest at the present time in curcumin as an
antineoplastic agent [89]. The IC50 values of 3-5 are lower than the figures for melphalan in
53% of the comparisons made. Curcumin contains an arylidene keto and aryl vinyl groups and
therefore bears some structural similarity to the compounds in series 3-5. In 72% of the
comparisons made, the IC50 values of 3-5 were lower than the figures for curcumin. In
particular, the average IC50 values of 3g and 4g are 13.5 and 14.2 times lower than the figure for
melphalan and are 63.8 and 66.8 times more potent than curcumin.
An evaluation of the biodata was undertaken with a view to determine if the compounds
varied in their potency towards each of the four cell lines. In other words, is tumor-selectivity
observed? The average IC50 values of 3a-g, 4a-g and 5 (the outliers 3h, i and 4h are omitted)
towards Molt4/C8, CEM, HeLa and L1210 cells are 2.79, 6.62, 6.24 and 7.70 µM, respectively.
Thus clearly Molt4/C8cells are more sensitive to 3a-g, 4a-g and 5 than CEM, HeLa and L1210
cells while the murine L1210 neoplasms are the most refractory. In general, tumor-selectivity
was demonstrated. The importance of this observation is that compounds which vary in their
potencies to different cells may have the capacity to display greater toxicity to tumors than
nonmalignant cells.
The biodata in Table 1 are encouraging and thus the extent to which representative
compounds are effective against other neoplasms was addressed. Many of the analogs in series
3-5 are effective against Molt4/C8 and CEM T-lymphocytes and L1210 leukemic cells. Hence
the cytotoxic potencies of representative compounds against T-cell derived lymphoma and
leukemic cell lines (Jurkat, CEM, SUP-T, HUT-102, Molt-3 and EL-4) were compared with B29

cell derived lymphoma and leukemic cells (Nalm-6, Raji, Ramos and BJAB). In addition, the YT
neoplasm, which is a natural killer-like leukemic cell line, was included in the array of cell lines.
In view of the high mortalities caused by breast and prostate cancers, the efficacy of various
analogs against several of these neoplastic cell lines was considered viz breast (MCF-7, MDA231 and HCC70) and prostate cancers (DU145, 22rv1 and LAPC4). Two non-transformed cell
lines were also utilized in order to observe the relative toxicity towards nonmalignant tissues
namely breast epithelial cells (MCF10A) and foreskin fibroblasts (Hs-27). The cells are of
human origin except for murine EL-4 cells and are non-adherent except for the breast, prostate
and Hs-27 cell lines which are adherent in nature.
The results obtained for representative compounds in series 3-5 are presented as a heat
map in Fig. 3 while specific figures are available in Appendix Tables 2.1 and 2.2. The following
figures in parentheses are the average of the percentage of dead cells caused by 3b, c, e-h, 4b, c,
e, f and 5 towards one or more cell lines. The following generalizations of the data obtained were
made. First, Fig. 2.3 reveals clearly the greater lethality of the compounds towards lymphoma
and leukemic cell lines (49.8) than either breast (11.9) or prostate (19.7) cell lines. The most
sensitive cells are Jurkat (81.9), CEM (78.3) and Ramos (76.9). In addition, the compounds are
more effective against B-cells (59.0) than T-cells (48.6). Secondly, the cytotoxic potencies of the
lymphatic and leukemic cells (49.8) and to a lesser extent the DU145, 22rv1 and LAPC4 prostate
cancers (19.7) compare favorably with the non-toxic effects of the compounds on the nontransformed Hs-27 control cell line (7.33). On the other hand, the toxicity of the compounds
towards MCF-7, MDA -231 and HCC70 breast cancer cells (11.9) is similar to the effect on the
MCF10A cell lines (8.50). Thirdly, somewhat surprising is the extent of cell death of the
lymphoma and leukemic cells being influenced more by the cell line than the structures of the
compounds as may be observed in Fig. 3. Thus the average percentage of dead lymphoma and
leukemic cells was within the relatively narrow range of 43.0e58.3. The most potent compounds
towards leukemia and lymphoma cells are 3f (58.3), 4e (56.4), 4f (53.4) and 3g (52.5) suggesting
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the importance of the 3,4-dimethoxy aryl substitution pattern present in 3f and 4f to cytotoxicity.
One may also note that the two most potent compounds towards prostate cancers are 3f (39.8)
and 4f (30.0). In summary, the compounds are toxic against a range of leukemic and lymphoma
cells which are non-adherent and therefore these compounds may have the capacity to combat
metastasis. In addition, the relatively low toxicity towards nonmalignant MCF10A and Hs-27
cells is encouraging.
The data generated in this study for the compounds in series 3-5 is that a number of these
dienones display marked cytotoxic potencies for various leukemia and lymphoma cell lines. A
previous study indicated that many of these compounds are very toxic towards human HCT116
and HT29 colon cancer cells [87]. Thus the next phase of the current investigation consisted of
examining additional colon cancers and leukemic cells in order to confirm their potency to these
tumors. Representative compounds in series 3-5 were evaluated against approximately 59 human
tumor cell lines from nine different neoplastic conditions, viz leukemia, melanoma and nonsmall cell lung, central nervous system, colon, ovarian, renal, prostate, and breast cancers [84].
Some of these data are presented in Table 2.2.
The results obtained confirm the marked cytotoxic potencies of most of the compounds
towards colon cancer cells. With regard to the IC50 values towards the five colon cancer cell
lines, no less than 86% are submicromolar and 29% are in the double digit nanomolar range. The
most potent compounds are 3g and 4g displaying average IC50 values of 70 and 60 nM,
respectively, which are 121 and 141 times lower, respectively, than 5-fluorouracil which is used
clinically in treating colon cancers. The same compounds have marked antileukemic properties
as the data in Table 2 reveals. In this case, the IC50 values are submicromolar and in the double
digit nanomolar range in 86% and 50% of the bioassays, respectively. The most potent
compounds are also 3g and 4g with average IC50 figures of 40 and 30 nM, respectively, which
are 1418 and 1890 times lower than the average IC50 value of melphalan which is used in
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treating various leukemias. In addition, 4c is a useful antileukemic lead compound displaying an
average IC50 value of 40 nM indicating that 4c has more than double the potency of 3c.
The final segment of this investigation was directed to gaining some ideas of the way in
which representative compounds caused cytotoxicity. The dienones 3f and 4f were chosen which
have the same aryl substituents but differ in the nature of the X-linker group. Many
antineoplastic agents exert their cytotoxicity by causing apoptosis [85]. Hence in order to explore
this possibility, CEM cells were treated with 3f and 4f for 24 h and the results were determined
by flowcytometry using annexin-FITC and Propidium stains. The results, which are portrayed in
Fig. 4, revealed that both 3f and 4f induce apoptosis and to a lesser extent necrosis. One may also
note that the extent of apoptosis and necrosis caused by 3f and 4f differs which may contribute to
some of the variations in the cytotoxic potencies of these two compounds.
There are two principal apoptotic signaling pathways, namely the intrinsic mitochondrial
and extrinsic death receptor routes. In the case of the mitochondrial pathway, apoptosis can be
induced by different mechanisms some of which involve activation of caspases while others do
not [90]. After incubation of CEM cells with either 3f or 4f, a cell permeable caspase-3
fluorogenic dye was employed. The intensity of the stain reveals the extent of caspase-3 activity
in cells with intact cell membranes. The result is presented in Fig. 2.5 which reveals that both
compounds activate caspase-3 which is an important way by which apoptosis takes place.
Apoptosis can also be caused by compounds affecting the mitochondrial membrane
potential (MMP). In the absence of any cytotoxic effects, the MMP is polarized. If 3f and 4f act
via the mitochondrial pathway, disruption of the MMP can take place leading to depolarization
which may be detected using the JC-1 dye. Fig. 2.6 reveals that both 3f and 4f cause significant
depolarization of CEM cells which indicates that these compounds cause apoptosis, at least in
part, via the mitochondrial pathway.
In summary, while the ways in which 3f and 4f exert their bioactivity are likely
multifactorial, this study has revealed that the compounds cause apoptosis by processes which
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include phosphatidylserine translocation, caspase-3 activation and disruption of the MMP which
is one the biochemical hallmarks of apoptosis.
2.4

Conclusions
This study has led to the discovery of a novel group of potent antineoplastic agents which

demonstrate toxicity to a diverse array of human tumors. The aryl substitution pattern has a
profound effect on cytotoxic potencies and in general the 4-fluoro, 4-chloroand 3,4,5-trimethoxy
analogs have the lowest IC50 values. The bioevaluations against a wide range of tumors revealed
that leukemias (Tables 2.1 and 2.2, Fig. 2.3), lymphomas (Table 2.1, Fig. 2.3) and colon cancers
(Table 2.2) are the most sensitive to these compounds while breast and prostate cancers are more
refractory (Fig. 2.3). Encouragingly, some of the representative compounds in series 3-5
displayed only marginal toxicity to nonmalignant MCF10A and Hs-27 cells. The cytotoxicity of
two representative compounds 3f and 4f towards CEM T-lymphocytes is caused, inter alia, by
interfering with the mitochondrial intrinsic pathway. Future studies include in vivo evaluations
of the promising lead molecules against different human leukemias, lymphomas and colon
cancer xenografts. New analogs and prodrugs based on series 3-5 possessing suitable
pharmacokinetic properties [91], [92] will be developed. The objective is to obtain one or more
preclinical candidates to treat conditions for which there are considerable unmet medical needs.
2.5

Experimental

2.5.1 Synthesis of series 3-5
The preparation of the compounds in series 3e5 has been described previously [82], [84].
The detailed characterization data for 3a-i, 4a-i and 5 and the 1H and 13C NMR spectra of three
representative compounds (one from each series) namely 3e, 4e and 5 are provided in the
Appendix Section.
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2.5.2 Statistical analyses
Linear and semilogarithmic plots were made between the IC50 values of 3a-i in the
Molt4/C8, CEM, HeLa and L1210 bioassays which are presented in Table 1 and the σ, π and MR
values of the aryl substituents using a commercial software package [93]. The same evaluation
was undertaken with the analogs 4a-h.
A description of the derivation of Kendall’s coefficient of concordance is presented in the
Appendix Section.
2.5.3 Evaluation of 3-5 against Molt4/C8, CEM, HeLa, and L1210 cells
A literature procedure was utilized to evaluate the compounds in series 3-5, melphalan
and curcumin against Molt4/C8, CEM, HeLa and L1210 cells [90]. In brief, different
concentrations of the compounds were incubated with the appropriate cell line in RPMI 1640
medium at 37ºC for 72 h (Molt4/C8, CEM T-lymphocytes and HeLa cells) or 48 h (L1210 cells).
Cell survival was determined using a Coulter counter. The IC50 values are expressed as the
mean + SD from the concentration -response curves of at least three independent experiments.
2.5.4 Evaluation of 3b, c, e-h, 4b, c, e, f and 5 against some lymphoma, leukemic, breast,
prostate and nonmalignant cells
A number of compounds were evaluated against some lymphoma, leukemic, breast,
prostate cancers and nonmalignant cells using a published procedure [94]. In brief, solutions of
the dienones in dimethylsulfoxide were added to different cell lines in RPMI media except in the
case of Hs-27 fibroblasts, DMEM was used. After 24 h incubation at 37ºC, cytotoxicity was
noted by the disruption of the cell membrane using Propidium iodide. The average cytotoxicity
of three independent experiments was expressed as the percentage of dead cells. These results
are presented in Appendix Tables 2.1 and 2.2.
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2.5.5 Evaluation of 3a-d, g, 4a, c, e, g, i and 5 against a panel of human tumor cells
The data in Table 2 was obtained by a literature procedure [95]. The GI50 figures are
IC50 values except for 3d (the IC50 values using four cell lines are greater than 32.4 µM) and 5fluorouracil (for three of the cell lines the IC50 values are in excess of 2.512 mM). All of the
data for the colon cancers and leukemic cells are IC50 values. The compounds were evaluated
against 59 cell lines except for 3a (60 cell lines) as well as 5 and 5-flurouracil (57 cell lines).
2.5.6 The induction of phosphatidylserine externalization, caspase activation, and
depolarization of the mitochondrial membrane potential in CEM cells by 3f and 4f
CEM cells (ATCC, Manassas, VA) were grown in RPMI-1640 medium (HyClone,
Logan, UT) supplemented with 10% heatinactivated fetal bovine serum (HyClone), 100 U/mL
penicillin and 100 µg/mL streptomycin (Lonza, Walkersville, MD). Cells grown exponentially
were counted and seeded into 24-well plate formats at a density of 50,000 cells in 500 µL culture
media per well. The dienones 3f and 4f were dissolved in dimethylsulfoxide and aliquots were
added to the plates containing the CEM cells in the culture media. All incubation conditions were
conducted in a humidified 5% carbon dioxide atmosphere at 37ºC. To guarantee high viability,
the cells were prepared and cultured as described previously [96]. All treatment and controls
were undertaken in triplicate.
2.5.7 Phosphatidylserine externalization assay
The evaluation of the ability of 3f and 4f to induce apoptosis in CEM cells was
undertaken as follows. CEM T-lymphocytes were incubated with 1 µM of 3f or 4f for 24 h and
then the cells from each well were collected in a pre-chilled cytometric tube, washed and
processed essentially as described previously [97]. In brief, cells were stained with a solution of
Annexin V-FITC and Propidium iodide (PI) in 100 µL of binding buffer (Beckman Coulter,
Miami, FL). After 15 min of incubation on ice in the dark, 400 µL of ice-cold binding buffer was
added to cell suspensions and immediately analyzed by flow cytometry (Cytomics FC 500,
Beckman Coulter, Miami, FL). These results are presented in Fig. 2.4.
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2.5.8 Caspase-3 assay
The activation of caspase-3 by 3f and 4f was demonstrated using the following
methodology. The CEM cells were seeded in 24-well plates vide supra and treated with 1 µM of
3f or 4f for 8 h. Caspase-3 activation was determined using a fluorogenic NucView 488 caspase3/7 substrate for living cells (Biotium, Hayward, CA) following the Vendor’s instructions. This
substrate is permeable to cells with intact plasma membranes and the emission of a green
fluorescent signal indicates caspase-3 activation in real-time via flow cytometry (Cytomics FC
500). The results obtained are portrayed in Fig. 2.5.
2.5.9 Mitochondrial membrane polarization assay
The depolarization of the mitochondrial membrane potential in CEM cells by 3f and 4f
was demonstrated by the following methodology. Using a concentration of 1µM, the dienones
were added to CEM cells and after incubation for 8 h, the cells were stained with 2µM of the JC1 fluorophore (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazoly- carbocyanine iodide,
MitoProbe, Life Technologies, Grand Island, NY) following the manufacturer’s protocol. This
result is presented in Fig.2.6.
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Figure 2.1: The structures of the compounds in series 1 and 2.
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Figure 2.2: The structures of the analogues 3-5.
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Table 2.1: Evaluation of 3a-i, 4a-h, and 5 against Molt4/C8, CEM, HeLa, and
L1210 cells.
IC50 (µM)a
Compound

Average
Molt4/C8

a

CEM

HeLa

L1210

3a

0.46 ± 0.11

0.75 ± 0.16

1.0 0± 0.10

4.46 ± 0.23

1.67

3b

0.08 ± 0.04

0.22 ± 0.14

0.38 ± 0.04

0.42 ± 0.23

0.28

3c

0.29 ± 0.01

0.79 ± 0.01

0.65 ± 0.44

0.55 ± 0.28

0.57

3d

8.46 ± 2.01

24.6 ± 4.20

27.00 ± 24.3 42.0 ± 5.40

25.5

3e

1.66 ± 0.21

7.72 ± 0.91

3.79 ± 3.29

9.09 ± 1.43

5.57

3f

0.78 ± 0.10

4.36 ± 3.06

4.43± 0.22

6.31 ± 3.46

3.97

3g

0.05 ± 0.02

0.33± 0.06

0.25 ± 0.16 0.18± 0.01

0.20

3h

33.1 ± 2.50

95.1± 69.10

59.90± 45.6

202 ± 16.00

97.5

3i

437 ± 8.00

276± 25.00

>500

297 ± 4.00

>378

4a

0.07 ± 0.01

0.20 ± 0.17

0.91 ± 0.07

1.23 ± 0.38

0.60

4b

1.58 ± 0.04

2.75 ± 0.67

5.61 ± 3.72

11.0 ± 2.5

5.24

4c

1.05 ± 0.62

1.06 ± 0.39

0.82 ± 0.17

0.85 ± 0.36

0.95

4d

23.5 ± 1.0

49.9± 17.7

39.80± 27.0 30.4 ± 8.8

35.9

4e

1.89 ± 0.03

3.44± 1.44

2.88 ± 2.72

5.38 ± 0.78

3.40

4f

0.39 ± 0.07

0.35 ± 0.06

0.37 ± 0.06

0.38 ± 0.18

0.37

4g

0.06 ± 0.02

0.28 ± 0.05

0.22 ±0.17

0.21 ± 0.08

0.19

4h

449 ± 4.00

369± 45.00

219 ± 17.00

>500

>384

5

1.45 ± 0.06

2.52 ± 1.24

5.54 ± 3.67

2.98 ± 1.81

3.12

Melphalan 2.81 ± 0.33

1.44 ± 0.20

1.70 ± 0.44

4.85 ± 0.87

2.70

Curcumin 6.46 ± 1.41 8.16± 1.66 21.20± 16.1 15.1 ± 1.6
12.7
The IC50 values are the concentrations required to inhibit tumor cell proliferation by 50%.
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Figure 2.3: Heat map illustrating the toxicity of the compounds.
The final tested concentration of 3b, c, e-h, 4b, c, e, f, and 5 compounds was 1µM
towards 19 cell lines after 24 h of treatment. The data was generated from three independent
determinations. MeV software was utilized to construct the heat map.
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Table 2.2: Evaluation of 3a-g, 4a, c, e, g, i and 5 against some human tumor cell lines. a

Compound

Colon cancer cells, IC50 (mM)

All cell lines,
c
IC50 (mM)

b

Leukemic cells, IC50 (mM)

b

COLO 205

HCC-2998

HCT-15

KM12

SW620

Ave

HL-60
(TB)

K-562

RPMI-8226

SR

Ave

0.31

0.36

0.19

0.3

0.04

0.07

0.19

0.2

0.2

0.03

0.02

0.11

3b

0.58

0.63

0.62

0.16

0.3

0.32

0.41

1.12

0.28

0.12

0.16

0.42

3c

0.22

0.16

0.31

0.14

0.21

0.18

0.2

0.19

0.13

0.05

0.02

0.1

3d

8.51

12.3

16.6

5.89

11.2

3.8

9.96

13.2

5.89

1.17

1.78

5.51

3g

0.06

0.07

0.1

0.07

0.06

0.03

0.07

0.07

0.03

0.02

0.02

0.04

0.24

0.16

0.17

0.17

0.13

0.05

0.14

0.29

0.05

0.13

0.03

0.13

4c

0.09

0.08

0.13

0.06

0.16

0.03

0.09

0.11

0.03

0.02

0.01

0.04

4e

0.19

0.17

0.3

0.08

0.17

0.15

0.17

0.23

0.1

0.03

0.05

0.1

4g

0.05

0.06

0.1

0.03

0.04

0.05

0.06

0.04

0.03

0.05

0.01

0.03

4i

1.66

1.66

1.74

1.17

0.69

0.76

1.2

1.74

0.53

0.35

0.46

0.77

5

0.19

0.19

0.18

0.2

0.16

0.06

0.16

0.25

0.04

0.04

0.04

0.09

5-Fluorouracil

29.5

3.39

5.75

6.61

7.94

18.6

8.46

85.1

126

3.55

60.3

68.7

Melphalan

19.1

32.4

52.5

36.3

57.5

26.9

41.1

0.38

195

28.2

3.24

56.7

a

3a

a

4a

a

The data for 3a and 4a have been published previously [83].

b

The IC50 values are the concentrations of the compounds

which inhibit tumor cell growth by 50%. c As indicated in the experimental section, the IC50 values of 3d and 5-fluorouracil towards a
few cell lines were not generated due to their being somewhat refractory to the compounds.
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Figure 2.4: 3f and 4f induce apoptotic cell death in a human CEM T-lymphocyte cell line as
detected by phosphatidylserine externalization.
The CEM cell line was treated with 1 µM concentration of 3f and 4f and controls (media
alone, 1% v/v DMSO, or 1 mM H2O2) for 24 h and the level of apoptosis induction was
measured by flow cytometry via Annexin V-FITC binding and Propidium iodide (PI) staining.
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(A) Apoptotic cell distribution is expressed as the sum of the percentages of both early and late
phases of apoptosis (Annexin V-FITC positive; white bars), whereas cells that were stained by
PIbut without FITC signal were considered necrotic cells (black bars). Analysis using the twotailed Student’s paired t-test of experimental compounds against untreated (*) and DMSO (+/+)
controls was consistently at the level of p < 0.001, respectively. Each bar represents the standard
deviation of the mean of three independent experiments. Panels B to F are representative flow
cytometric analyses utilized to estimate the distribution of apoptosis/necrosis cells, where the
FL1 or FL2 detectors settings were accommodated on the x- and y-axes, respectively. Data
analysis from quadrant regions in the dot plots are interpreted as follows: the N1 quadrant
represents necrotic cells (PI positive): N2 represents cells undergoing late apoptosis (PI and
Annexin V-FITC positive); N3 represents unstained viable cells; and N4 represents cells in early
apoptosis (Annexin V-FITC positive). Approximately, 3000 events were acquired and analyzed
using CXP software (Beckman Coulter).
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Figure 2.5: 3f and 4f induce apoptotic cell death via caspase-3 activation in the CEM T
lymphocyte cell line

Cells were incubated with compounds (1 µM each) for 8 h and then labeled with
NucView 488 caspase-3 substrate and examined via flow cytometry. In panel A, the total
numbers of cells with active caspase-3 are graphed along the y axis, whereas different treatments
are plotted along the x-axis. Each bar represents the standard deviation of the mean of three
independent experiments. Analysis using the two-tailed Student’s paired t-test of the
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experimental compounds against untreated (*) and DMSO (+/+) controls was consistently p <
0.01, respectively. Panels B to F are representative flow cytometric analyses dot plots used to
determine the distribution of cells with active caspase-3, where the FL1 and FL2 detectors
settings were set on the x and y-axes, respectively. Cells exposed to 2 mg/ml of camptothecin
(CPT) were used as positive controls. Untreated and DMSO solvent treated cells were analyzed
concurrently. Approximately, 10,000 events were acquired and analyzed using CXP software
(Beckman Coulter).
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Figure 2.6: 3f and 4f mediated cytotoxicity appears to be initiated via mitochondrial ΔΨm
disruption in CEM T-cells.
Cells were treated for 8 h with the compounds (1 µM) and changes in the mitochondrial
ΔΨm were determined by staining with the aggregate forming lipophilic cationic fluorophore JC1 and monitored via flow cytometry. After dissipation of mitochondrial ΔΨm, the JC-1 reagent
emitted a green fluorescence signal, whereas cells with polarized mitochondrial membrane
emitted a red signal.Cells emitting a green fluorescence signal (y-axis) versus treatment type (xaxis) are depicted. Analysis using the two-tailed Student’s paired t-test of the experimental
compounds against untreated (*) and DMSO (+/+) controls was consistently at the level of p <
0.001, respectively. Each bar represents the standard deviation of the mean of three independent
assays. Cells exposed to the mitochondrial stressor CCCP (50 mM) were used as positive
controls. DMSO solvent and untreated controls were also analyzed in parallel. Approximately
10,000 events were captured and analyzed per sample using CXP software (Beckman Coulter).
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2.6
Appendix
Characterization of 3,5-bis(arylidene)-4-piperidone dimers (3a-i, 4a-i and 5)
Melting points were determined on a Gallenkamp instrument and are uncorrected. 1H and
13C NMR were recorded using a Bruker Avance 500 MHz spectrometer equipped with a 5mm
BBO probe. Chemical shifts (δ) are reported in ppm. Elemental analyses were undertaken using
an Elementer CHNS analyzer. The 1H and 13C NMR spectra of three representative compounds
(one from each series) namely 3e, 4e and 5 are presented.
1,2-bis[3,5-bis(Benzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3a)1
Yield: 62%; mp (chloroform/methanol) 246 oC; 1H NMR(500 MHz, DMSO-d6): δ
7.72(s, 2H, 2×=CH), 7.56 (s, 2H, 2×=CH), 7.53(t, 4H, Ar-H), 7.49(d, J=7.07 Hz, 2H, Ar-H),
7.45(m, 6H, Ar-H), 7.39(m, 8H, Ar-H), 4.48(d, J=23.28Hz, 8H, 4×NCH2; 13C NMR (125MHz,
DMSO-d6):184.7, 162.6, 137.9, 137.5, 134.4, 134.1, 131.4, 131.0, 130.9, 130.7, 130.2, 130.1,
129.3, 129.2, 46.4, 41.6,; MS (ESI) m/z: 627 (M+Na)+. Anal.calcd for C40H32N2O4.H2O: C
77.17; H 5.14; N 4.50, found: C 77.05; H 4.87; N 4.42.
1,2-bis[3,5-bis(4-Fluorobenzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3b)2
Yield: 67%; mp (chloroform/methanol) 253 oC; 1H NMR (500 MHz, CDCl3): δ 7.73(s,
2H, 2×=CH), 7.57 (s, 2H, 2×=CH), 7.37(q, 4H, Ar-H), 7.25 (q, 4H, Ar-H), 7.18 (t, 4H, Ar-H),
7.098(t, 4H, Ar-H), 4.63 (s, 4H, 2×NCH2), 4.51 (s, 4H, 2×NCH2). Anal.calcd for
C41H26Cl8N2O4.H2O: C 53.93; H 3.09; N 3.07 %, found: C 53.84; H 2.98; N 2.74%.

1,2-bis[3,5-bis(4-Chlorobenzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3c)2
Yield: 61%; mp (methanol) 289 oC; 1H NMR (500 MHz, CDCl3): δ 7.72(s, 2H,
2×=CH), 7.54 (s, 2H, 2×=CH), 7.46 (d, J=8.40 Hz, 2H, Ar-H), 7.37(d, J=8.37 Hz, 2H, Ar-H ),
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7.31(d, J=8.42 Hz, 4H, Ar-H), 7.20(d, J=8.38 Hz, 4H, Ar-H), 4.62 (s, 4H, 2×NCH2), 4.52 (s,
4H, 2×NCH2). Anal.calcd for C40H28Cl4N2O4.3 H2O: C 60.26; H 3.54; N 3.51 %, found: C
60.35; H 3.70; N 3.15%.
1,2-bis[3,5-bis(3,4-Dichlorobenzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3d)2
Yield: 64%; mp (chloroform/methanol) 271 oC; 1H NMR (500 MHz, CDCl3): δ 7.68 (s,
2H, 2×=CH), 7.55 (s, 1H, =CH), 7.53 (s, 1H, =CH), 7.46 (d, J=8.15 Hz, 6H, Ar-H), 7.41(d,
J=1.71 Hz, 2H, Ar-H), 7.20 (dd, J=1.67Hz, J=1.71Hz, 2H, Ar-H), 7.05 (dd, J=1.71 Hz, J=1.77
Hz, 2H, Ar-H), 4.67 (s, 4H, 2×NCH2), 4.56 (s, 4H, 2×NCH2).

Anal.calcd for

C40H24Cl8N2O4: C 54.58; H 2.75; N 3.18 %, found: C 54.52; H 2.90; N 2.95 %.
1,2-bis[3,5-bis(4-Methylbenzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3e)2
Yield: 53%; mp (chloroform/methanol) 275 oC; 1H NMR (500 MHz, CDCl3): δ 7.79(s,
2H, 2×=CH), 7.65 (s, 2H, 2×=CH), 7.29 (d, J=7.70 Hz, 8H, Ar-H), 7.18(q, 8H, Ar-H), 4.53 (d,
J=15.61 Hz, 8H, 4×NCH2), 2.44 (s, 6H, 2×CH3), 2.28 (s, 6H, 2×CH3). 13C NMR (125 MHz,
CDCl3): δ 185.04(CO), 162.73(CON), 140.31(C=C-Ph), 140.22(C=C-Ph), 139.15(C=C-Ph),
138.29(C=C-Ph), 131.57(Ar-C),131.07(Ar-C), 130.67(Ar-C), 130.33(Ar-C), 129.72(Ar-C),
129.62(Ar-C), 129.46(Ar-C), 129.00(Ar-C), 46.07(CH2NCO), 42.05(CH2NCO), 21.53(CH3),
21.43(CH3). Anal.calcd for C44H40N2O4.1.5 H2O: C 76.76; H 6.30; N 4.07 %, found: C 76.46;
H 6.39; N 3.93%.
1,2-bis[3,5-bis(3,4-Dimethoxybenzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3f)2
Yield: 60%; mp (chloroform/methanol) 282 oC; 1H NMR (500 MHz, CDCl3): δ 7.71(s,
2H, 2×=CH), 7.42 (s, 2H, 2×=CH), 6.99 (d, J=8.47 Hz, 4H, Ar-H), 6.94(d, J=8.08 Hz, 2H, ArH), 6.80(m, 6H, Ar-H), 4.70 (s, 4H, 2×NCH2), 4.64 (s, 4H, 2×NCH2), 4.00 (s, 6H, 2×OCH3),
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3.96 (d, 12H, 4×OCH3), 3.74 (s, 6H, 2×OCH3). Anal.calcd for C48H48N2O12.H2O: C 66.75; H
5.84; N 3.24 %, found: C 66.31; H 5.62; N 3.06%.
1,2-bis[3,5-bis(3,4,5-Trimethoxybenzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3g)2
Yield: 57%; mp (ethanol) 273 oC; 1H NMR (500 MHz, CDCl3): δ 7.63(s, 2H, 2×=CH),
7.44 (s, 2H, 2×=CH), 6.66 (s, 4H, Ar-H), 6.49 (s, 4H, Ar-H), 4.75 (s, 4H, 4×NCH2), 4.68 (s,
4H, 4×NCH2), 3.96 (s, 12H, 4×OCH3), 3.94 (s, 9H, 3×OCH3), 3.88 (s, 9H, 3×OCH3), 3.84 (s,
6H, 2×OCH3). Anal.calcd for C52H56N2O16 : C 64.72; H 5.85; N 2.90 %, found: C 64.95; H
6.16; N 2.78%.
1,2-bis[3,5-bis(4-Methoxybenzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione (3h)2
Yield: 71%; mp (chloroform/methanol) >300 oC; 1H NMR (500 MHz, CDCl3): δ 7.74(s,
2H, 2×=CH), 7.58 (s, 2H, 2×=CH), 7.35 (d, J=8.65 Hz, 4H, Ar-H), 7.22 (d, J=8.63 Hz, 4H, ArH), 6.98 (d, J=8.71 Hz, 4H, Ar-H), 6.91 (d, J=8.67 Hz, 4H, Ar-H), 4.60 (s, 4H, 2×NCH2), 4.53
(s, 4H, 2×NCH2), 3.90 (s, 6H, 2×OCH3), 3.76 (s, 6H, 2×OCH3). Anal.calcd for C44H40N2O8 :
C 72.91; H 5.56; N 3.86 %, found: C 72.57; H 5.94; N 3.75%.
1,2-bis[3,5-bis(4-(N,N-Dimethylamino)benzylidene)-4-oxo-piperidin-1-yl]ethane-1,2-dione
(3i)2
Yield: 46%; mp (chloroform/methanol) >300 oC; 1H NMR (500 MHz, CDCl3): δ 7.75(s,
2H, 2×=CH), 7.65 (s, 2H, 2×=CH), 7.33 (d, J=8.75 Hz, 4H, Ar-H), 7.21(d, J=8.71 Hz, 4H, ArH), 6.73 (d, J=16.93 Hz, 8H, Ar-H), 4.58 (s, 4H, 2×NCH2), 4.54 (s, 4H, 2×NCH2), 3.08 (s, 12H,
4×NCH3), 2.95 (s, 12H, 4×NCH3). Anal.calcd for C44H40N2O4.1.5 H2O: C 76.76; H 6.30; N
4.07 %, found: C 76.46; H 6.39; N 3.93%.
1,3-bis-[3,5-bis(Benzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4a)1
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Yield: 65%; mp (acetone) 201 oC; 1H NMR (500 MHz, DMSO-d6): δ

7.72(s, 2H,

2×=CH), 7.57(s, 2H, 2×=CH), 7.53(d, J=4.18Hz, 8H, Ar-H), 7.47 (m, 12H, Ar-H), 4.62(d,
J=21.13Hz, 8H, 4×NCH2), 3.46(s, 2H, CH2); 13C NMR (125MHz, DMSO-d6):186.3,
165.9,136.6, 136.5, 134.7, 134.5, 132.6, 132.5, 131.0, 130.9, 130.1, 130.0, 129.3, 129.2, 47.0,
42.4; MS (ESI) m/z: 641 (M+Na)+. Anal.calcd for C41H34N2O4.H2O: C 77.27; H 5.65; N 4.39,
found: C 77.31; H 5.50; N 4.47.
1,3-bis-[3,5-bis(4-Fluorobenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4b)2
Yield: 56%; mp (chloroform/methanol) >300 oC; 1H NMR (500 MHz, CDCl3): δ 7.81
(s, 2H, 2×=CH), 7.75 (s, 2H, 2×=CH), 7.49(q, 4H, Ar-H), 7.33 (q, 4H, Ar-H), 7.18 (t, 4H, ArH), 7.12 (t, 4H, Ar-H), 4.84 (s, 4H, 2×NCH2), 4.79 (s, 4H, 2×NCH2), 3.22 (s, 2H, CH2).
Anal.calcd for C41H30F4N2O4.H2O: C 69.42; H 4.27; N 3.95 %, found: C 69.58; H 4.30; N
3.71%.
1,3-bis-[3,5-bis(4-Chlorobenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4c) 2
Yield: 58%; mp (chloroform/methanol) 260 oC; 1H NMR (500 MHz, DMSO-d6): δ 7.64
(s, 2H, 2×=CH), 7.60 (s, 2H, 2×=CH), 7.57 (d, J=11.46 Hz, 4H, Ar-H), 7.54 (d, J=7.60 Hz, 4H,
Ar-H), 7.49 (q, 8H, Ar-H), 4.62 (d, 8H, J=10.15 Hz, 4×NCH2), 3.51 (s, 2H, CH2). Anal.calcd
for C41H30Cl4N2O4.2.5 H2O: C 61.38; H 3.77; N 3.49 %, found: C 61.10; H 3.69; N 3.30%.
1,3-bis-[3,5-bis(3,4-Dichlorobenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4d) 2
Yield: 65%; mp (chloroform/methanol) 236 oC; 1H NMR (500 MHz, CDCl3): δ 7.71 (s,
2H, 2×=CH), 7.63 (s, 2H, 2×=CH), 7.56 (q, 8H, Ar-H), 7.51 (d, J=8.29 Hz, 2H, Ar-H), 7.30 (d,
J=1.45 Hz, 2H, Ar-H), 7.31 (dd, J=1.45 Hz, J=1.53 Hz, Ar-H), 7.15 (dd, J=1.48 Hz, 2H, Ar-H),
4.78 (d, 8H, J=6.72 Hz, 4×NCH2), 3.30 (s, 2H, CH2). Anal.calcd for C41H26Cl8N2O4. H2O: C
53.93; H 3.09; N 3.07 %, found: C 53.84; H 2.98; N 2.74%.
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1,3-bis-[3,5-bis(4-Methylbenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4e) 2
Yield: 43%; mp (chloroform/methanol) 251 oC; 1H NMR (500 MHz, CDCl3): δ 7.81 (s,
2H, 2×=CH), 7.74 (s, 2H, 2×=CH), 7.40 (d, J=7.90 Hz, 4H, Ar-H), 7.27 (d, J=7.60 Hz, 4H, ArH), 7.21(q, 8H, Ar-H), 4.89 (s, 4H, 2×NCH2), 4.65 (s, 4H, 2×NCH2), 3.15 (s, 2H, CH2), 2.43 (s,
6H, 2×CH3), 2.41(s, 6H, 2×CH3). 13C NMR (125MHz, CDCl3): δ 186.39(CO), 165.30(CON),
140.31(C=C-Ph),

140.17(C=C-Ph),

138.62(C=C-Ph),

137.34(C=C-Ph),

131.86(Ar-C),

131.39(Ar-C), 130.88(Ar-C), 130.53(Ar-C), 130.45(Ar-C), 130.39(Ar-C), 130.33(Ar-C),
129.68(Ar-C),

129.61(Ar-C),

128.77(Ar-C),

46.79(CH2NCO),

43.85(CH2NCO),

40.54

(COCH2CO), 21.53(CH3). Anal.calcd for C45H42N2O4.H2O: C 77.94; H 6.40; N 4.04 %,
found: C 77.94; H 6.63; N 3.98%.
1,3-bis-[3,5-bis(3,4-Dimethoxybenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4f) 2
Yield: 65 %; mp (chloroform/methanol) >300 oC; 1H NMR (500 MHz, DMSO-d6): δ
7.86 (s, 4H, 4×=CH), 7.17 (s, 4H, Ar-H), 7.13 (s, 8H, Ar-H), 4.54 (s, 8H, 4×NCH2), 3.84 (d,
J=7.27 Hz, 24H, 8×OCH3), 3.48 (s, 2H, CH2). Anal.calcd for C49H50N2O12.7 H2O: C 59.69;
H 6.54; N 2.84 %, found: C 59.82; H 6.18; N 2.71%.
1,3-bis-[3,5-bis(3,4,5-Trimethoxybenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4g) 2
Yield: 53%; mp (chloroform/methanol) 115 oC; 1H NMR (500 MHz, CDCl3): δ 7.78 (s,
2H, 2×=CH), 7.74 (s, 2H, 2×=CH), 6.72 (s, 4H, Ar-H), 6.58 (s, 4H, Ar-H), 4.96 (s, 4H,
2×NCH2), 4.90 (s, 4H, 2×NCH2), 3.92 (d, J=15.37 Hz, 30H, 10×OCH3), 3.86 (s, 6H, 2×OCH3),
3.37 (s, 2H, CH2). Anal.calcd for C53H58N2O16.H2O: C 63.83; H 6.07; N 2.81 %, found: C
63.84; H 6.27; N 2.51%.
1,3-bis-[3,5-bis(4-Methoxybenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4h) 2
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Yield: 61%; mp (chloroform/methanol) 245 oC; 1H NMR (500 MHz, CDCl3): δ 7.80 (s,
2H, 2×=CH), 7.73 (s, 2H, 2×=CH), 7.48 (d, J=8.6 Hz, 4H, Ar-H), 7.29 (d, J=10.17 Hz, 2H, ArH), 6.98 (d, J=8.49 Hz, 4H, Ar-H), 4.85(s, 4H, 2×NCH2), 4.72 (s, 4H, 2×NCH2), 3.88 (d, J=7.72
Hz, 12H, 4×OCH3), 3.22 (s, 2H, CH2). Anal.calcd for C45H42N2O8.4 H2O: C 66.59; H 5.22;
N 3.45 %, found: C 66.68; H 5.38; N 3.27%.
1,3-bis-[3,5-bis(4-Hydroxybenzylidene)-4-oxo-piperidin-1yl]propane-1,3-dione (4i) 2
Yield: 56%; mp (chloroform/ethanol) >300 oC; 1H NMR (500 MHz, DMSO-d6): δ 7.64
(s, 2H, 2×=CH), 7.60 (s, 2H, 2×=CH), 7.57 (d, J=11.46 Hz, 4H, Ar-H), 7.54 (d, J=7.60 Hz, 4H,
Ar-H), 7.49 (q, 8H, Ar-H), 4.62 (d, 8H, J=10.15 Hz, 4×NCH2), 3.51 (s, 2H, CH2). Anal.calcd
for C41H34N2O8.4.5 H2O: C 64.46; H 5.68; N 3.67 %, found: C 64.59; H 5.31; N 3.59%.
1,3-bis-[3,5-bis(benzylidene)-4-oxo-piperidin-1yl]propane (5) 2
Yield: 63 %; mp (acetone) 135 oC; 1H NMR (500 MHz, CDCl3): δ 7.81(s, 4H, 4×=CH),
7.39 (m, 20H, Ar-H), 3.78 (s, 8H, 4×NCH2), 2.54 (t, 4H, 2×CH2), 1.60 (p, 2H, CH2). 13C NMR
(125 MHz, CDCl3): δ 187.34 (CO), 136.57 (C=C-Ph), 135.20 (C=C-Ph), 133.11 (C=C-Ph),
130.40 (Ar-C), 129.05 (Ar-C), 128.60(Ar-C), 55.38 (NCH2CH2), 54.97 (NCH2-piperidone),
25.91 (CH2). Anal.calcd for C41H38N2O2: C 83.36; H 6.48; N 4.74 %, found: C 83.74; H 6.79;
N 5.05%.

1

H and 13C NMR spectra for representative compounds from the series 3-5
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Kendall’s coefficient of concordance
The equation used to obtain the coefficient of concordance is derived as follows. In this
case the cytotoxin i is given the rank rij where j is the cell line, and there are N cytotoxins and M
cell lines. Thus the total rank R given to cytotoxin i is

, and the mean value of

these ranks is
The sum of the squared deviations, (S), is defined as:
Kendall’s coefficient of concordance (W) is:

…(1) If all the cell lines

produce identical rankings, then W is 1. If there is no agreement, then W is 0.
When two or more compounds have the potencies (i.e., there are ties in the rankings),
then equation 1 will understate the degree of concordance and must be adjusted. The correction
factor (Tj) is defined as

, in which ti is the number of tied ranks in the ith group

of tied ranks (the number of cases of equal potency at a specific IC 50 value) and gj is the number
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of tie values. If there are no tied ranks for cell line j then this will be 0. Using this correction for
ties, Kendall’s coefficient of concordance as:

…(2).
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Table 1. Evaluation of 3b,c,e-h, 4b,c,e,f and 5 against various lymphoma and leukemic cell linesa
% dead cells
Compound Jurkat
CEM
3b
87.8
85.3
3c
78.5
59.9
3e
80.7
68.4
3f
84.8
88.1
3g
78.7
84.1
3h
72.0
71.9
4b
87.1
92.4
4c
85.3
83.0
4e
85.5
85.7
4f
83.9
77.6
5
76.3
64.5
Average
81.9
78.3

a

SUP-T
35.6
18.1
18.8
33.0
38.2
15.2
24.9
21.1
23.6
31.0
21.2
25.5

HUT-102
64.4
31.4
13.9
50.9
50.5
6.7
58.5
20.4
50.9
51.6
10.0
37.2

Molt-3
3.1
0.4
0.8
31.8
30.3
49.6
2.6
20.6
21.3
2.6
27.4
17.3

EL-4
34.7
52.5
43.5
46.5
33.8
71.7
47.7
55.4
66.9
43.7
65.3
51.1

Nalm-6
61.6
59.0
59.5
60.7
67.6
62.6
51.9
68.6
67.6
63.9
49.2
61.1

Raji
33.5
35.7
41.5
56.3
55.7
69.1
35.3
32.7
46.5
50.8
31.9
44.5

Ramos
53.3
82.9
84.4
87.4
65.1
53.7
78.6
86.3
83.0
88.6
82.1
76.9

BJAB
61.8
43.1
41.5
62.8
60.9
45.8
61.2
49.9
60.2
61.0
39.4
53.4

YT
17.1
21.5
20.1
39.2
13.0
5.8
19.2
16.8
29.1
32.3
6.6
20.1

Average
48.9
43.9
43.0
58.3
52.5
47.7
50.9
49.1
56.4
53.4
43.1
49.8

A concentration of 1 μM of each compound was incubated with different cell lines for 24 h at 37° C. The figures of the percentage of

dead cells are the average of three independent experiments.
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Table 2. Evaluation of 3b,c,e-h, 4b,c,e,f and 5 against some breast and prostate cancer cells and nonmalignant cellsa
Compound
3b
3c
3e
3f
3g
3h
4b
4c
4e
4f
5
Average

a

% dead cells
MCF-7 MDA231
16.2
5.5
17.8
10.0
0.0
9.3
17.7
4.6
43.2
4.7
16.2
0.6
0.2
0.4
19.5
32.7
19.1
8.6
23.0
1.8
43.5
20.1
19.7
8.94

HCC70
6.6
8.4
11.9
3.9
7.3
14.7
3.1
7.8
10.1
2.1
4.3
7.29

Average
9.43
12.1
7.07
8.73
18.4
10.5
1.23
20.0
12.6
8.97
22.6
11.9

MCF10A
7.7
2.2
9.3
5.8
7.6
9.9
7.0
3.1
15.4
6.1
19.4
8.50

DU145
15.2
33.1
26.0
45.7
41.3
11.4
38.4
40.3
21.9
67.4
19.4
32.7

22rv1
30.1
13.6
16.2
38.2
3.4
0.0
18.8
1.7
6.3
2.0
1.7
12.0

LAPC4
11.3
27.0
2.4
35.4
9.7
1.9
11.1
1.0
7.0
20.6
5.7
12.1

Average
18.9
24.6
14.9
39.8
18.1
4.43
22.8
14.3
11.7
30.0
8.93
19.7

Hs-27
0.6
0.0
12.0
10.2
15.4
0.6
0.3
5.7
26.5
6.4
2.9
7.33

A concentration of 1 μM of each compound was incubated with different cell lines for 24 h at 37° C. The figures of the
percentage of dead cells are the average of three independent experiments.
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Chapter 3: A novel curcumin analogue sensitizes leukemia and lymphoma
cells to apoptosis via increased TNF-α and DAPK1 expression
Using different cell death assays, we have identified a curcumin-like analogue with
potent activity against hematological malignancies. The analogue was developed from recently
discovered novel class of curcumin-like molecules designed by structure-based chemical
modifications of 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore. The cell death mechanism
was determined to be mediated by apoptosis through detection of phosphatidylserine
externalization, mitochondrial depolarization, and caspase activation. RT-PCR experiments
revealed a time-dependent upregulation of Death Associated Protein Kinase-1 (DAPK-1), Tumor
Necrosis Factor-α (TNF-α), and Fas-Associated Death Domain (FADD). ELISA and western
blots further confirmed the upregulation of the DAPK-1 and TNF-α proteins. Interestingly, cell
death regulation among T and B cell lines resulted different and probably this can be a promising
therapeutic advantage that needs to be verified in the future.
1.1

Introduction
Recently, we have published about the discovery of a new class of curcumin-like

molecules selective against hematological malignancies [98], [82]. The overall objective of these
investigations was the development of at least one promising prototypic cytotoxic molecule
identified to possess drug-likeness properties.

A candidate cytotoxic compound was now

identified based on its ability to broadly induce cell death against a panel of hematological
cancers at low micromolar concentrations. Characterization of this promising compound has
revealed cell death mediated by apoptosis, as evidenced by phosphatidylserine externalization,
mitochondrial depolarization, and caspase activation. RT-PCR experiments demonstrated timedependent upregulation of Death Associated Protein Kinase-1 (DAPK-1), Tumor Necrosis
Factor-α (TNF-α), and Fas-Associated Death Domain (FADD). ELISA and western blots further
confirmed the upregulatation of the DAPK-1 and TNF-α. Publications about curcumin have also
shown the upregulation of DAPK-1, but have not evidenced TNF involvement [99].This is the
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first report about a curcumin-like compound inducing both cell death regulators in Jurkat cells.
Further, it is evidenced here that Nalm-6 cells die also through DAPK-1. Nonetheless, other
genes different than TNF, but related to cell death receptor pathway, such as FADD, are
upregulated in Nalm-6 cells in response to this novel curcumin-like analogue.
The expression of DAPK is found to be epigenetically suppressed in several tumors and
its death-inducing function has been demonstrated by its over-expression in cell lines [100],
[101]. Thus, DAPK-1 has been characterized as a calcium/calmodulin-regulated serine/threonine
kinase and considered a potential therapeutic target and important tumor suppressor in deciding
the fate of cellular functions such as cell death, survival, motility, and autophagy [102], [103],
[104]. Studies by Wu, B. et al have shown that DAPK-1 was required for curcumin-induced cell
cycle arrest and apoptosis. This was approached by siRNA knockdown showing attenuation of
curcumin-induced inhibition of STAT3 and NF-κB and diminished curcumin-induced caspase-3
activation [105]. In addition, DAPK-1 expression and activity has been found to be dysregulated
in blood malignancies, non-small cell lung, pancreatic, head and neck carcinomas to mention a
few

[100, 106], [107], [108], [109], [110]. Especially, DAPK silencing occurs with more

frequency in B-cell lymphomas [111], [112]. As a tumor suppressor, DAPK-1 down-regulates
XIAP and Nuclear Factor-kappa B (NF-κB), and as a pro-apoptotic kinase, contains a death
domain that participates in multiple apoptotic signaling pathways, including the Tumor Necrosis
Factor-α (TNF-α), Fas, and Interferon- γ (IFN- γ) pathways [113], [105], [114] . The downregulation of DAPK-1 by transfecting siRNA in Jurkat cells resulted in reduced susceptibility to
Fas-induced apoptosis suggesting the involvement of DAPK-1 in the extrinsic apoptosis pathway
in lymphocytes [115].
DAPK-1 is found associated with actin microfilaments and its activation can occur
through dephosphorylation of Ser-308 by TNF-α [116], [117], [118]. Induction of TNF-α occurs
in response to various stimuli, including lipopolysaccharide (LPS) or small-molecules and can
result in apoptosis, increased survival, or inflammatory processes [119], [120], [121]. The
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apoptotic pathway of TNF-α occur when this cytokine binds to the extracellular domain of
Tumor Necrosis Factor Receptor-1 (TNFR-1) promoting the release of Silencer Of Death
Domain (SODD) for the trimerization of TNFR-1 with TNFR-associated death domain
(TRADD) [122] , [123], [124]. This in turn recruits the receptor interacting protein (RIP), TNFRassociated factor 2 (TRAF-2), and Fas-Associated Death Domain (FADD) [125], [126]. These
adaptor proteins recruit pro-caspase-8, which is subsequently activated and induces
mitochondrial depolarization and downstream caspases [67], [127]. The survival and
inflammatory activity of TNF-α is under the control of TNFR-1 and TRAF-2 [128]. The binding
of TRAF-2 to TNFR-1 can result in the activation of Mitogen-Activated Protein Kinase (MAPK)
and c-Jun N-terminal Kinase (JNK) [129], [130]. Another major signaling event is the activation
of NF-κB that takes place after TRAF-2 and RIP binding [131]. MAPK, NF-κB and JNK are
known to induce transcription of inflammatory, immunomodulatory, anti-apoptotic, and
proliferative genes such as Bcl-2 and XIAP [132]. Nonetheless, DAPK-1 antagonizes TNF-α
pro-inflammatory and survival signaling by inhibition of NF-κB activation [133]. Upon the
blockade of NF-κB, TNF-α can stimulate a strong pro-apoptotic signal inducing internalization
of FADD and caspase-8 recruitment leading to the activation of the caspase cascade and
apoptosis [134]. Thus, DAPK-1 possesses potential therapeutic capabilities regulating cell death
signals which can offer opportunities for the development of anti-cancer drugs.
DAPK-1 has been recently found to be induced by curcumin, a known anticancer
compound that unfortunately has low systemic biovailability that lowers it potential therapeutic
and chemopreventive effects [105], [68], [72]. To overcome this limitation, analogues of
curcumin’s have been synthesized that show promising anti-cancer activity [69], [135]. In this
study, a curcumin-like analogue was found to have potent activity against hematological
malignancies. Exposure of Jurkat and Nalm-6 human lymphoid cells to the analogue resulted
indifferential upregulation of TNF-α and DAPK-1, as well as several other pro-apoptotic genes.
We utilized a commercial RT-PCR array system (Human Apoptosis RT² Profiler PCR Array,
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Qiagen, MD) to detect the effects of the analogue on 84 apoptosis-related genes in Jurkat and
Nalm-6 cells at several time points. In addition, western blot analysis to detect the gene products
of some of the activated proteins revealed that the up regulation of the genes resulted in an
increase in protein levels of DAPK-1. This analysis detected the highest levels of DAPK1 by 8
hrs of treatment with the analogue.
3.2

Methods

3.2.1 Curcumin analogue synthesis and reagents
A new series of curcumin analogues were synthesized and obtained from Dr. J.R.
Dimmock (University of Saskatchewan, Saskatchewan, Canada). The compounds were received
in powder and prepared as 1 mM stock solution dissolved in DMSO and kept at -20°C. Final
solvent concentrations on the cultured cells were 1% (v/v), which had negligible effect on any of
the parameters studied. Hoechst 33342 (Hoechst; Invitrogen, Eugene, OR); and Propidium
iodide (PI; MP Biomedicals, Solon, OH) stock solutions were prepared in PBS, diluted with cell
culture medium, and added to each experimental well at a final concentration of 1 µg/ml for each
dye. Annexin V-FITC (Beckman Coulter, Marseille, France), JC-1 dye (Molecular Probes, OR,
U.S.), and DEVD-NucView™ 488 substrate (Biotium, Inc., Hayward, CA) were diluted
according to the respective manufacturer instructions.

3.2.2 Cell lines and culture conditions
Eleven lymphoid cancer cell lines and two normal non-transformed cell line were utilized
to test the cytotoxic potential of the analogue. Each lymphoid cancer cell line selected for this
study was a representative hematological malignancy with their unique genetic heterogeneity.
The lymphoid cancer cell lines were: Jurkat, SUP-T1, HuT 102, MOLT-3, and CCRF-CEM
human T–cell lymphomas and leukemias (obtained from ATCC, Manassas, VA, USA); Nalm-6
(DSMZ, Braunschweig, Germany), Raji, Ramos, and BJAB human B –cell lymphomas and
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leukemias (ATCC, Manassas, VA, USA); YT Nk-Like1 human natural killer leukemia cell line
(DSMZ, Braunschweig, Germany); and EL4 mouse T -cell lymphoma (ATCC, Manassas, VA,
USA). The culture medium for the lymphoid cancer cells was Roswell Park Memorial Institute
(RPMI; HyClone). The normal non-transformed cell lines were Hs27 and MCF-10A, obtained
from normal human foreskin fibroblasts (ATCC, Manassas, VA, USA) and normal mammary
gland (ATCC, Manassas, VA, USA), respectively. Non-transformed cell lines were selected to
test the cytotoxicity of the analogue on tissues from normal origin. Growth media for Hs27 was
Dulbecco's Modified Eagle Medium (DMEM; HyClone, Logan, UT) and DMEM/F12
supplemented with EGF (100 mg/ml), Hydrocortizone (1mg/ml), CholeraToxin (1mg/ml) and
Insulin (10mg/ml) for MCF-10A. All types of culture media were supplemented 10% heat
inactivated serum and with 100U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml
amphotericin B (Lonza, Walkersville, MD). The incubation conditions for the cells were 37ºC in
humidified 5% carbon dioxide (CO2) atmosphere, in a regular water jacketed incubator.
To prepare the experimental multi-well plates and to guarantee high viability, the Hs27
and MCF-10A cells were washed with fresh media to eliminate cell debris and floating dead
cells. Hs27 and MCF-10A cells were harvested from culture flasks by adding 2 ml of 0.25%
trypsin solution (Invitrogen, Carlsbad, CA), diluted in serum free DMEM, and incubated for
approximately 15 min at 37°C. Trypsin was neutralized by addition of culture media with 10%
serum. Cells were then centrifuged to remove the neutralized trypsin and transferred to a new
culture flask and replenished with complete growth media. When necessary, the viability of the
lymphoid cancer cells was increased by using Ficoll-Paque™PLUS density gradient [136]. After
centrifugation at 400xg for 20 min at 25°C, live cells at the interface between the Ficoll-Paque
and the cell suspension were collected and washed with fresh culture media. These lymphoid
cancer cells were then expanded by starting a new culture. Only cultures containing cell
viabilities of 95% or higher were used for the cytotoxicity studies. This was assured by Flow
cytometry by staining the cells with PI.
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3.2.3 Screening assays (DNS and MTS)
The Differential Nuclear Staining (DNS) screen is a high-throughput screening technique
that uses two differential dyes to identify cytotoxic compounds [137]. Hs27, MCF-10A, and
lymphoid cancer cells were seeded in black flat-bottomed plastic 96-well assay plates (BD
Biosciences, Rockville, MD) at densities of 5,000 cells/well for adherent cell lines and 10,000
cells/well for suspension cells in 100 µl of culture media/well. The analogue was tested at the
final concentration of 1µM (diluted in 1% v/v DMSO) per well according to CC50 values
previously examined by cytotoxicity assays. The compound was dispensed into the wells via a
robotic pipette (epMotion 5070, Eppendorf, New York, NY).

As a positive control for

cytotoxicity, cells were treated with 300 µM final concentration of H2O2 and not commercial
drugs. This was required to achieve constancy in every cytotoxicity assay, since images are
segmented based on controls. Commercial drugs are not useful as positive controls in this type of
assay, because they are not always toxic or do not have the same cytocidal effects on certain
cancer cells lines in vitro.

As negative control and for normalization purposes cells were

treated with 1% v/v DMSO. Untreated cells were also included as negative controls and as an
indicator of cell viability during the incubation period. Cells exposed to the experimental
compounds, plus their controls were incubated for a total of 20hr under the conditions described
above, and immediately followed by image acquisition. One hour prior imaging, the mixture of
Hoechst 33342 and PI was added. Three times overall standard deviation in the assay was used
as a cutoff threshold for assessing cytotoxicity of the compounds. All screening was carried out
in triplicates.
MTS assay (CellTiter 96 AQueousOne Solution Cell Proliferation Assay; Promega,
Madison, WI) was effectuated to confirm the results obtained by DNS assay. Adherent cells were
seeded at a density of 5,000 cells/well in 100 µL medium. The number of cells seeded per well
was in accordance with the manufacturer’s instructions. For suspension cells, the number of
seeded cells per well was 10,000 cells/well. The analogue was tested at the same final
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concentration (1 µM) in presence of 1% v/v DMSO and dispensed into the wells with the same
robotic pipette utilized for the DNS assay. After 69 hr of incubation, 20 µl of the MTS reagent
were added to each well and subsequently incubated for additional 3 hr, completing 72 hr of
incubation. The length of incubation period and the amount of MTS reagent added were in
accordance with the manufacturer’s instructions.

Absorbance was read at 490 nm with a

reference wavelength of 650 nm using a microplate reader (VERSAmax tunable microplate
reader, MDS, Inc., Toronto, Canada). Control wells containing 100 µL of culture medium and
MTS reagent were used as blank to subtract background absorbance. Data were expressed as
percentage of cell viability relative to DMSO (solvent control) treated cells. The results were
expressed as percentages of dead cells. Compounds with cytotoxicity lower than three times
overall SD in the assay were considered.
3.2.4 Image acquisition and analysis for DNS assay
The BDPathway 855 Bioimager system and its associated AttoVision v1.6.2 software
(BD Biosciences, Rockville, MD) were utilized for image collection and analysis. After Hoechst
and PI dye mixture addition and incubation, images were captured with a 380/10 nm 535 LP nm
for Hoechst and 555/28 nm 645/75 nm for PI excitation/emission filter sets. Images from each
well were acquired using a 10x/ NA 0.75 dry objective. In order to obtain sufficient cell
numbers for statistically robust data, images from nine (3x3 montage) contiguous fields were
obtained per well. Under these settings the images were subsequently analyzed using the
AttoVision software. To define nuclei as individual units or regions of interest (ROIs), preprocessing filters and intensity thresholds were applied for image segmentation. Segmented
images were subjected to data classification by the use of the AttoVision software. The
percentage of dead cells was calculated from the total number of ROIs per well. Cell nuclei
emitting fluorescence signal from both Hoechst and PI (fluorescence co-localization) were
considered as dead/dying cells, while cells emitting only Hoechst signal were counted as live
cells. Data was classified by the use of the AttoVision software to identify compounds with
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cytotoxic activity. Heat maps were constructed using the MeV Multiexperiment Viewer Software
v.4.9.
3.2.5 Generation of dose-response curve and determination of CC50 value
The CC50 was defined as the in vitro compound concentration causing 50% of cell
population death as compared to solvent treated cells after 20hr of incubation. The same type of
cancerous lymphoid cell lines and non-transformed cell lines were plated into black bottom 96well plates at same densities and conditions used in the DNS assay. The CC50 values were
obtained as previously described by Elie, BT. et al [94]. To create dose-response curves and
determine the 50% cytotoxic concentration (CC50), the identified hit was tested at several
concentrations. Data was normalized by subtracting from each experimental value the average
percentage of dead cells from six wells treated with 1% v/v DMSO. The compound’s
concentrations closest to the 50% cytotoxicity value were plotted and using the linear regression
equation exact CC50 value was determined.
3.2.6 Apoptosis assay
Apoptosis assays were performed on lymphoid cancerous cell lines to test whether or not
the analogue was killing the cancerous cells by apoptosis. Apoptosis detection was by
Flowcytometry (FC 500 Series Beckman Coulter) using Annexin V-FITC (Beckman Coulter,
Marseille, France) in combination with PI. Manufacturer’s protocol was followed. Untreated
cells, 1µM Curcumin, 1µM EF-24, 300 µM H2O2, and 1% v/v DMSO were included as controls
and incubated for a total of 24 hrs.
3.2.7 Mitochondrial membrane potential assay
JC-1 dye (Molecular Probes, OR, U.S.) was used to study the involvement of
mitochondria during early stages of apoptosis. Jurkat cells were seeded in 24-well-plates at a
density of 3x104 cells in 1 mL of media per well. Cells treated with 1µM analogue, 1µM
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), 1% v/v DMSO, and untreated cells were
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incubated for different time points (4, 7, and 12 hrs). Then, the cells were transferred to Flow
cytometry tubes. JC-1 stock solution was prepared at 200 µM concentration and 1.5µL were
added to each Flowcytometry tube. After 15 min incubation at 37 ºC, the tubes were processed
by Flowcytometry (FC 500 Series Beckman Coulter).
3.2.8 Caspase-3/7 and -8 activity assays
Jurkat cells were seeded at a density of 100 cells/µL in 2.5 mL of media in 24-wellplates. The analogue was tested in a final concentration of 1µM. As positive controls, 20 µM
Campthothecin and 10 µM Curcumin were used. These compound’s concentrations were used
according to previously determined CC50 values. As negative controls, 1% v/v DMSO-treated
and untreated cells were included. For the caspase-3/7 and -8 assays, time-course experiments
were designed from 0-20 hr in the presence of DEVD-NucView™ 488 substrate (Biotium, Inc.,
Hayward, CA) or fluorescein active caspase-8 staining kit (Abcam, Cambridge, MA) according
to the instructions of each manufacturer. Caspase-3/7 and-8 activity was analyzed by
Flowcytometry (FC 500 Series Beckman Coulter) and data was analyzed with CXP software
(Beckman Coulter).
3.2.9 RNA extraction and RT-PCR array
Jurkat and Nalm-6 cells (1x107) were treated with 1µM analogue, 10µM curcumin, and
1% v/v DMSO for different time points. Total RNA was extracted from cells using the RNeasy
Mini Kit (Qiagen, Austin, TX, USA) and quantified using NanoDrop-1000 Spectrophotometer.
Total RNA (1µg) per sample was converted into cDNA by using the RT2 First Strand Kit
(Qiagen, Austin, TX, USA). RT2 Profiler PCR Arrays for human apoptosis (PAHS-012Z) and
RT2 Fluor SYBR Green (Qiagen, Austin, TX, USA) were utilized in accordance to
manufacturer’s instructions to study the expression of 84 apoptotic genes. The RT-PCR was
carried out in an iCycler Real-Time PCR Detection System (Bio-Rad, Hercules, CA) using the
following conditions: 95ºC for 10 min, followed by 40 cycles of 95ºC for 15 sec, 60ºC for 1 min,
95ºC for 1 min, 55ºC for 1 min, followed by melt curve analysis 80 cycles of 55ºC +0.5ºC per
68

cycle for 10 min, finally hold at 4ºC. RT-PCR results were confirmed by designing specific
custom-made primers (Supp.Table:3.3) and using them instead of using the primers in the RT2
Profiler PCR Arrays. The same RT-PCR cycling conditions and buffers contained in the kits
where used.
3.2.10 Western blots
Jurkat cells were grown on T-75 bottles in the conditions described before. Cell viability
was assured by staining cells with PI and processing them through Flowcytometry. When
necessary, viability was optimized via Ficol-Paque™.

Cells (1x10^6 per treatment) were

incubated for different time-points with 1µM NC2496, 10µM curcumin, and 1% v/v DMSO.
Treated cells were collected, washed once with cold PBS and resuspended in 100 μl of Lysis
buffer.

Following

cell

lysis,

total

protein

was

quantified

using

NanoDrop-1000

Spectrophotometer. Measurements were done in triplicate and calculations for protein
normalization were done. Samples were mixed with Laemmli sample loading buffer (Bio-Rad,
Hercules,CA) and boiled for 3 min at 95°C. Whole cell lysates extracts (50 μg protein/sample)
were subjected to a 12% SDS polyacrylamide gel electrophoresis and electroblotted onto PVDF
membrane. Membrane was blocked overnight at 4ºC with 5% BSA (Sigma-Aldrich,St. Louis, MI
). The membrane was then incubated with the primary antibodies: rabbit monoclonal anti-human
DAPK-1 (1:1000, no. TA310390, OriGene, Rockville, MD), rabbit anti-human Bcl-2 (1:1000,
no. 2870, Cell Signaling Technology, Danvers, MA), or mouse anti-human GAPDH (1:10000,
no.10r-g109a, Fitzgerald Industries International, North Acton, MA). To normalize the results,
membranes were blotted for GAPDH. Proteins were detected with horseradish peroxidase-linked
secondary antibodies (1:5,000) and SuperSignal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL). WCIF ImageJ software (http://www.uhnresearch.ca/facilities/wcif/index.htm) was
used for densitometry analysis.
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3.2.11 ELISA assay
Jurkat cells (1x107) were treated with 1µM analogue, 10µM curcumin, and 1% v/v
DMSO for different time points. Cells and media were collected and centrifuged at 13,000 rpm
x10 min at 4º C. Human TNF-α Elisa Kit (Thermo Scientific, Rockford, IL) was utilized to
detect in the media of treated and control cells the levels of TNF-α. The assay was performed in
triplicates and in accordance to the manufacturer’s instructions.
3.2.12 Statistical Analysis
All experiments were performed in biological triplicates. Averages and standard
deviations were calculated in Excel (Microsoft). Outliers, student’s t-test, and p values were
calculated using Graph Pad software.
3.3.

Results and Discussion

3.3.1 Identification of a novel potent curcumin analogue
The cytotoxic potential of 19 curcumin analogues was evaluated by DNS using a panel of
13 cell lines (Supp.Fig.3.1a). Jurkat, Nalm-6, CEM and Ramos were the most sensitive cell lines
as indicated by red and black squares which represent 50-100% cytototoxicity. Less sensitive cell
lines were Sup-T1, Molt-3, YT, MCF-10A, and Hs27 as represented by green and black squares.
To further confirm previous findings obtained by using DNS assay, an MTS assay was carried
out (Supp.Fig.3.1b).

Non-cancerous foreskin fibroblasts (Hs27 cell line) and non-cancerous

breast cell line (MCF-10A) were used for DNS and MTS assays. MTS assay with a long (72 hrs)
incubation time, was needed to determine if the difference in cytotoxicity seen between the
adherent cell lines and the non-adherent blood cancer cells for some of the compounds, might be
explained simply on the basis of slower proliferation rate of the adherent cells. This effect is
well-known for certain chemotherapeutic agents that show an apparent preferential targeting of
highly proliferating cells [138]. As shown in Supplementary Figure 3.2b, certain compounds
demonstrated a higher toxicity for the non-cancerous Hs27 and MCF-10A cells when
administered for an extended period of time. However, other compounds showed selectivity for
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blood cancerous cells when comparing DNS versus MTS. Thus, there were few analogues with
selective toxicity for blood cancerous cells. Among these analogues, NC2496 was selected based
on its selectivity for blood cancerous cell lines and broad range cytotoxic spectrum against these
malignancies.
3.3.2 NC2496 induces apoptosis at low micromolar concentrations
We have identified a novel cytotoxic compound potent against hematological
malignancies (Fig. 3.1). The potency of the analogue is shown by its low CC50 (≤1 µM), broad
spectrum against different types of hematological malignancies, and selectivity towards
neoplasms (Table 3.1 and S. Fig. 3.1). Phosphatidylserine externalization assays carried out in
Jurkat and Nalm-6 cells revealed apoptosis occurrence at 24 hrs of incubation with the analogue
(Fig. 3.2). Incubation of Jurkat and Nalm-6 cells with 1µM concentration of the analogue
induced more than 50% of apoptosis in Jurkat and Nalm-6 cell populations (Fig. 3.2a & 3.2b).
Further apoptotic cell death indicators such as caspase-3/7 and -8 (Fig. 3.3b & 3.3c) and
mitochondrial assessment (Fig.3.3a) were realized to confirm apoptosis occurrence. The optimal
time for mitochondrial depolarization occurrence in Jurkat cells was determined by time-point
experiments (data not shown). Incubation of the cells for 6-8 hrs with 1µM concentration of the
analogue was enough to induce 80% of mitochondrial depolarization in Jurkat cells (Fig. 3.3a).
To assess caspase-3/7 and caspase-8 activity, Jurkat cells were treated with 1µM NC2496
or left untreated (controls) for different time points. The study revealed caspase-8 activation at a
maximum of 6-8 hr in the presence of the analogue (Fig. 3.3b). Caspase-3/7 activation was found
greatest at 20 hr incubation with the analogue (Fig. 3.3c).
In summary, these findings suggested apoptosis occurrence through up-stream effectors
at 8 hrs of treatment up to 20hrs when caspase-3/7 is activated. Activation of caspase-8 was
hypothesized to occur through cell death receptors which induce caspase-8, mitochondrial
depolarization, and ultimately caspase-3 activation.
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3.3.3 NC2496 induces programmed cell death through TNF-α and DAPK-1
After identifying apoptosis occurrence induced by NC2496, we decided to characterize in
deep the apoptotic cell death pathway induced by the compound in Jurkat and Nalm-6 cells. We
carried out RT-PCR arrays to screen changes in gene expression upon incubation with the
analogue. RT-PCR arrays were carried out at different time points (4, 8, 12 hrs) and showed upregulation of apoptotic genes and down-regulation of anti-apoptotic genes (Fig. 3.4, Supp. Table
3.1, & Supp. Table 3.2).
Significant up-regulated genes were DAPK-1, TNF, and FADD; while XIAP and Bcl-2
variants were down-regulated (Supp. Table 3.1 & Supp. Table 3.2). Comparison of the RT-PCR
results from Jurkat and Nalm-6 revealed differences among the expression levels of some genes
(Supp. Table 3.2). Consequently, we hypothesize that differences in gene expression among
different cell types in response to the insult of the compound, are due to the distinctive
inalienable features of each cell type. Realization of additional RT-PCRs but with custom-made
primers confirmed the identified up-regulated genes (Fig.3.4 & Supp. Table 3.3). Our results
showed that NC2496 exhibits apoptosis triggered by signals from the exterior of the cell by
members of TNF superfamily death receptors (Fig. 3.6). Death receptor activation was evidenced
by TNF, Fas-Associated protein with Death Domain (FADD), and Tumor necrosis factor
receptor type 1-associated DEATH domain (TRADD) up-regulation (Fig. 3.4), and by caspase-8
activation (Fig.3b). Up-regulation of TNF death receptors has been proven to be beneficial for
tumor regression and/or tumor growth delay as demonstrated in experiments of mice xenotransplanted with BJAB and Jurkat cancer cell lines [139]. In addition, we assessed the TNF-α
expression levels through ELISA assays and it was confirmed elevated levels of the cytokine
(Fig.3.5a). Although implicated in inflammation, TNF-α can induce apoptosis mediated by
antagonists like DAPK-1.
Since we have previously observed up-regulation of DAPK-1 gene, we confirmed its
expression through westernblot. We have found in this study timely-dependent induction of
DAPK-1 by NC2496. This was demonstrated by RT-PCR (Fig. 3.4 & Supp. Tables 3.1 &3.2)
72

and by westernblot (Fig.3.5b). The anti-inflammatory and apoptotic role of DAPK-1 induced by
NC2496 was confirmed through the down-regulation of Bcl-2 (Fig. 3.5b) and through downregulation of XIAP (Supp. Table 3.1). DAPK-1 apoptotic role has been confirmed previously by
its involvement in the interferon–induced apoptosis through the induction of Fas or TNF [140],
[141], [103], [142], [143]. Furthermore, overexpression of DAPK-1, have shown to induce
apoptotic morphological changes, such as cell rounding, shrinkage, and blebbing [103], [144],
[145]. In addition to apoptosis-promoting activity, several evidences indicate that DAPK-1 plays
an important role in tumor suppression. First, the expression of DAPK is frequently lost in
various tumor cell lines and tissues such as B cell lymphomas [146], [147]. Second, DAPK is
capable of suppressing c-myc, Bcl-2, E2F-induced oncogenic transformation or anti-apoptotic
genes [148]. Third, in an experimental metastasis model, the expression level of DAPK-1 was
inversely correlated with the metastatic activities of the tumors, and reintroduction of DAPK-1
into the highly metastatic tumors suppressed their ability to form metastases in mice [141]. In
addition, a study demonstrated that DAPK-1 is capable of activating p53-mediated apoptotic
pathway through a mechanism that requires p19 ARF [148]. In summary, DAPK-1 apoptotic
and anti-inflammatory activity has been demonstrated by many studies. In accordance, it was
demonstrated by us the apoptotic and anti-inflammatory roles of DAPK-1 over TNF-α through
the down-regulation of inhibitors of apoptosis (Supp. Table 3.1, Fig. 3.4 & 3.5) and through the
involvement of downstream effectors achieving apoptosis (Fig.3).
Another important aspect that deserves to be pointed out is the observed difference
among Jurkat (T-cell) and Nalm-6 (B-cell) cell lines when treated with the analogue. In
Supplementary Figure 2 can be noted differences among the expression levels of TNF in Jurkat
and Nalm-6 cell lines. Jurkat cells showed double amount of TNF expression levels than Nalm-6
cells. In addition, many more types of TNF receptors were upregulated in Jurkat than in Nalm-6
cells. It is also important to notice the expression levels of caspase-8 and caspase-2/RIPK1
domain containing adaptor with death domain that were induced in Nalm-6 cells. Highly
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expressed levels of NOL3 (nucleolar protein 3 (apoptosis repressor with CARD domain)) could
possibly repress death receptor effectors and the mitochondrial pathways in Nalm-6 cells. NOL3
has the ability to antagonize both with the extrinsic (death receptor) and the intrinsic
(mitochondria/ER) death pathways [149], [150], [151]. Although the upregulation of NOL3, this
was unable to detract the apoptotic activity of the analogue in Nalm-6 cells. Apparently, different
pathways of cell death can follow after the administration of the analogue and this seems can be
given by distinctive features of the cell lines.
3.4

Conclusions
Our findings suggest that NC2496 offers potent cytotoxic advantages over curcumin. The

in vitro cytotoxic response of NC2496 is achieved at 1µM in 24 hrs vs. 10µM curcumin in 24
hrs. The potency and selectivity of NC2496 is given by the recruitment of cell death receptor
members and pro-apoptotic regulators. Although, curcumin regulates many apoptotic signaling
pathways, it does not stimulate TNF. The activation of this potent cytokine can produce negative
effects, but under proper regulation can induce potent cytotoxic responses. We have discovered a
curcumin analogue capable of inducing upregulation of DAPK-1, a potent kinase considered a
tumor suppressor in charge of deciding the fate of cell death.

This novel analogue efficiently

engages the execution of apoptotis by TNF under the guidance of DAPK-1, thus achieving
targeted elimination of hematological cancerous cells. Discovery of compounds with novel
structures and cytotoxic pathways can be an opportunistic way of fine-tuning cancerous cells
who escape from death.
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Figure 3.1: Pharmacophore
utilized to synthesize the analogues.
CH3

Table 3.1: Anticancer activity of the analogue against some hematological cancer cell lines

a

The analogue, EF-24 and curcumin
b
were incubated for 24 hrs. Results were
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Figure 3.2: The effect of NC2496 in Jurkat and Nalm-6 cell lines.
Apoptosis induction in Jurkat (A) and Nalm-6 (B) was assessed at 24 hrs of incubation
with 1µM of the analogue. Curcumin and EF-24 were included as reference compounds. 1% v/v
DMSO and 1mM H2O2 were included as negative and positive controls, respectively.
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Figure 3.3: Apoptotic cell death indicators.
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Mitochondrial depolarization (A), caspase-8 (B), and capase-3/7 assays (C) were
performed as indicators of apoptotic cell death occurrence in Jurkat cells. The assays were
performed at different time points and different reference compounds were used in each assay. In
all three assays 1µM NC2496, 1%V/V DMSO, and 1mM H2O2 were utilized. CCCP was
utilized at a concentration of 50µM. Curcumin was utilized at the determined CC50
concentration of 10 µM.
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Figure 3.4: Gene-expression profiling during NC2496 and curcumin-induced apoptosis.
Jurkat (A) and Nalm-6 (B) cells were treated for 8 and 12 hrs with 1µM NC2496, 10µM curcumin and 1%V/V DMSO.
Profiling results are the mean of three independent assays. Expression levels of GAPDH were used as the internal housekeeping gene
control and to normalize variability between samples. In addition, expression values obtained with the analogue or curcumin were
normalized to the values obtained with cells treated with DMSO.
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A.

B.

Figure 3.5: DAPK-1 and TNF-α proteins are the expression products of NC2496 cell death induction.
A. ELISA assay was performed to confirm the expression levels of TNF-α at 12 hrs of treatment with 1µM NC2496, 10µM
curcumin, 25µM Cisplatin, and 1% V/V DMSO. B. DAPK-1 expression was confirmed by westernblot. Bcl-2 expression was found
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to be reduced by treatment of curcumin and the analogue for 12 hrs. α-Gapdh was used as loading control for westernblot. ImageJ
software version 1.47q (Wayne Rasband, National Institutes of Health, USA) was used for the densitometry analysis.

Figure 3.6: Proposed cell death mechanism of NC2496.
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From apoptosis, caspases, ELISA, westernblots, and qRT-PCR assays the cell death mechanism of NC2496 was elucidated to
occur through downstream and upstream apoptotic effectors involving TNFR.
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3.5 Appendix

A.

B.

S. Fig. 3.1: Discovery of cytotoxic curcumin analogues against hematological malignancies.
A. The cytotoxic potential of 19 curcumin analogues was studied in 13 cell lines by DNS.
The compounds were tested at a final concentration of 1 uM and incubated for 20 hrs. The red
color represents higher percentage of cytotoxicity (100%); black 50%, and green lower
cytotoxicity (0%). Distinctively, Jurkat, CCRF-CEM, Nalm-6, and Ramos cell lines were highly
affected by the compounds. B. MTS screen assay was carried out in Hs27 and MCF-10A cell
lines. The analogues were tested at a final concentration of 1 uM and incubated for 72 hrs. Black
color represents around 50% percentage of anti-proliferation and green low percentage of death.
NC2496 was selected because we were focused on those analogues without cytotoxic effects on
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non-cancerous cell lines, but with potent and broad cytotoxic effects on various blood cancerous
cells. MeV software was used to construct the heat maps.
S. Table 3.1: Regulation of anti-apoptotic and apoptotic genes by NC2496.
Fold regulation (Normalized over DMSO)
Anti-apoptotic Genes

4 hrs

8 hrs

12 hrs

BCL2L1

2.89

±1.16

2.22

±0.67

1.62

±0.47

IGF1R

2.76

±3.36

3.19

±0.72

1.61

±1.37

AKT1

2.48

±0.71

2.18

±0.66

1.50

±0.29

XIAP

2.11

±0.61

1.23

±0.62

1.21

±0.24

NAIP

2.00

±0.51

1.46

±0.52

1.14

±0.54

BAG1

1.61

±0.30

1.25

±0.66

1.16

±0.06

NFKB1

1.56

±0.46

1.93

±0.54

0.97

±0.50

BNIP3L

1.55

±0.06

1.49

±0.82

1.12

±0.16

BFAR

1.46

±0.22

-1.09

±1.54

1.12

±0.16

BIRC3

1.38

±0.11

2.07

±0.58

1.00

±0.68

BIRC2

1.35

±0.52

1.15

±0.62

1.28

±0.19

BNIP2

1.32

±0.00

1.62

±0.64

1.20

±0.40

TNFRSF1B

1.33

±0.22

-1.05

±0.66

1.89

±1.05

NOL3

1.23

±0.05

1.71

±0.62

1.18

±0.12

BRAF

0.80

±1.62

1.11

±0.65

1.00

±0.24

ABL1

0.57

±1.69

1.71

±0.59

1.40

±0.27

BIRC6

0.37

±1.70

1.74

±0.67

0.90

±0.35

BNIP3

0.33

±1.24

1.44

±0.62

1.33

±0.26

BCL2

0.24

±2.19

2.26

±0.57

0.96

±0.19

BCL2L2

0.13

±1.62

1.60

±0.70

1.34

±0.06

RIPK2

-0.23

±2.74

-1.80

±1.31

0.60

±0.09

BAG3

-0.54

±1.63

-2.78

±2.45

1.37

±1.39

BCL2A1

-1.24

±4.78

-3.48

±0.00

0.16

±0.19

MCL1

-1.49

±0.23

-2.00

±0.98

1.01

±0.56
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BIRC5

-1.71

±0.20

1.32

±0.79

1.25

±0.06

Continuation of Table 3.1
Fold regulation (Normalized over DMSO)
Apoptotic Genes

4 hrs

8 hrs

12 hrs

CD27

3.52

±1.52

1.74

±0.80

1.74

±0.00

CASP2

2.66

±0.40

2.51

±0.62

1.28

±0.49

TNFRSF25

2.41

±1.20

1.93

±0.73

1.59

±0.00

CIDEB

2.58

±1.04

2.07

±0.65

1.15

±0.11

CASP8

2.25

±0.67

1.65

±0.60

1.43

±0.68

CASP10

2.14

±0.54

1.80

±0.61

1.35

±0.33

BAD

1.96

±0.67

1.77

±0.65

1.76

±0.34

FAS

1.91

±0.08

1.49

±0.63

1.11

±0.57

TP53

1.66

±2.75

1.49

±0.59

1.14

±0.17

CASP3

1.44

±0.37

1.15

±0.55

0.82

±0.42

TRAF3

1.76

±0.27

1.32

±0.57

1.18

±0.12

APAF1

2.74

±0.51

2.93

±0.84

1.59

±1.07

BCL2L11

2.01

±0.23

2.38

±0.61

1.62

±0.54

TRAF2

1.93

±0.72

2.11

±0.70

1.62

±0.47

TNFRSF10B

1.84

±0.31

2.38

±0.72

1.20

±0.35

FADD

1.73

±0.38

3.36

±0.76

1.65

±1.23

TNFSF8

1.72

±0.74

1.07

±0.64

1.72

±0.89

TNF

1.65

±0.31

4.07

±0.55

1.81

±0.61

CFLAR

1.60

±0.24

2.11

±0.66

1.43

±0.61

CASP6

1.48

±0.06

1.11

±0.90

1.36

±0.27

CASP7

1.45

±0.56

1.97

±0.58

1.87

±0.18

CYCS

1.43

±0.62

2.00

±0.59

1.64

±0.32

DAPK1

1.42

±5.69

3.48

±1.40

1.88

±1.53

NOD1

1.36

±0.17

2.00

±0.62

1.34

±0.51

TNFRSF21

1.36

±0.16

1.65

±0.60

1.23

±0.83

BCL10

1.29

±0.05

2.42

±0.86

1.07

±0.36
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LTBR

1.24

±0.19

2.38

±0.54

1.29

±0.37

CD40LG

1.19

±0.20

2.04

±0.70

1.19

±0.06

TP53BP2

1.16

±0.19

1.97

±0.58

1.14

±0.85

CASP9

1.15

±0.13

1.19

±1.62

1.25

±0.18

BAX

1.13

±0.18

2.14

±0.76

1.28

±0.19

CD70

1.13

±0.14

-1.68

±1.28

0.90

±0.46

TNFRSF1A

0.86

±1.74

2.07

±0.59

1.54

±0.59

DFFA

0.58

±1.39

1.27

±0.59

1.20

±0.00

TRADD

0.57

±1.69

3.08

±0.64

2.02

±1.44

TNFSF10

0.53

±4.0

1.74

±0.51

1.29

±0.31

LTA

0.50

±1.94

1.57

±0.58

0.99

±0.51

CRADD

0.44

±1.42

1.25

±0.89

1.39

±0.14

IL10

0.27

±2.51

-3.48

±0.00

2.82

±3.48

CASP1

0.15

±2.44

-1.19

±0.91

0.85

±0.25

PYCARD

-0.31

±2.61

-1.19

±1.02

0.92

±0.18

CIDEA

-0.38

±1.47

-2.30

±0.88

2.06

±2.37

TNFRSF10A

-0.38

±1.58

-2.69

±0.43

2.07

±2.23

TNFRSF9

-0.38

±1.42

-2.93

±0.50

1.90

±2.24

TNFRSF11B

-0.38

±1.42

-3.48

±0.00

2.23

±2.64

CASP5

-0.38

±1.42

-3.48

±0.00

2.68

±3.17

CASP14

-0.38

±1.42

-2.83

±0.60

2.50

±2.96

FASLG

-0.44

±2.32

-2.00

±0.54

2.46

±2.44

BCL2L10

-0.47

±1.47

-3.48

±0.00

3.62

±4.29

CD40

-0.62

±2.31

-4.00

±0.00

2.08

±2.46

HRK

-0.65

±1.45

-1.83

±1.20

0.97

±0.41

CASP4

-1.18

±0.15

-1.30

±0.92

1.09

±0.61

BID

-1.20

±0.05

-1.23

±0.80

0.94

±0.18

GADD45A

-1.27

±0.16

1.41

±0.82

1.18

±0.29

BAK1

-1.80

±0.51

-1.41

±1.25

1.11

±0.79

AIFM1

-1.16

±0.24

1.25

±0.68

1.03

±0.20

TP73

-0.74

±1.66

2.83

±0.61

1.93

±0.09
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DIABLO

0.47

±1.42

1.34

±0.56

1.34

±0.07

BIK

0.62

±1.44

1.25

±0.67

1.46

±0.28

S. Table 3.2: Regulation of apoptotic and anti-apoptotic genes by NC2496 a.
Fold Change
Unigene
Hs.431048
Hs.424932
Hs.525622
Hs.552567
Hs.370254
Hs.377484
Hs.523309
Hs.485139
Hs.624291
Hs.193516
Hs.150749
Hs.227817
Hs.516966
Hs.283672
Hs.737004
Hs.735863
Hs.435556
Hs.591054
Hs.475055
Hs.731943
Hs.127799
Hs.744872
Hs.150107
Hs.592515
Hs.144873
Hs.131226
Hs.600998
Hs.2490
Hs.5353
Hs.466057
Hs.368982
Hs.141125
Hs.138378
Hs.213327
Hs.654616
Hs.9216
Hs.599762
Hs.329502
Hs.355307

Refseq
NM_005157
NM_004208
NM_005163
NM_001160
NM_004322
NM_004323
NM_004281
NM_001188
NM_004324
NM_003921
NM_000633
NM_004049
NM_138578
NM_020396
NM_006538
NM_004050
NM_016561
NM_001196
NM_001197
NM_001166
NM_001165
NM_001168
NM_016252
NM_004330
NM_004052
NM_004331
NM_004333
NM_033292
NM_001230
NM_012114
NM_032982
NM_004346
NM_001225
NM_004347
NM_032992
NM_001227
NM_001228
NM_001229
NM_001242

Symbol
ABL1
AIFM1
AKT1
APAF1
BAD
BAG1
BAG3
BAK1
BAX
BCL10
BCL2
BCL2A1
BCL2L1
BCL2L10
BCL2L11
BCL2L2
BFAR
BID
BIK
BIRC2
BIRC3
BIRC5
BIRC6
BNIP2
BNIP3
BNIP3L
BRAF
CASP1
CASP10
CASP14
CASP2
CASP3
CASP4
CASP5
CASP6
CASP7
CASP8
CASP9
CD27

Description
C-abl oncogene 1, non-receptor tyrosine kinase
Apoptosis-inducing factor, mitochondrion-associated, 1
V-akt murine thymoma viral oncogene homolog 1
Apoptotic peptidase activating factor 1
BCL2-associated agonist of cell death
BCL2-associated athanogene
BCL2-associated athanogene 3
BCL2-antagonist/killer 1
BCL2-associated X protein
B-cell CLL/lymphoma 10
B-cell CLL/lymphoma 2
BCL2-related protein A1
BCL2-like 1
BCL2-like 10 (apoptosis facilitator)
BCL2-like 11 (apoptosis facilitator)
BCL2-like 2
Bifunctional apoptosis regulator
BH3 interacting domain death agonist
BCL2-interacting killer (apoptosis-inducing)
Baculoviral IAP repeat containing 2
Baculoviral IAP repeat containing 3
Baculoviral IAP repeat containing 5
Baculoviral IAP repeat containing 6
BCL2/adenovirus E1B 19kDa interacting protein 2
BCL2/adenovirus E1B 19kDa interacting protein 3
BCL2/adenovirus E1B 19kDa interacting protein 3-like
V-raf murine sarcoma viral oncogene homolog B1
Caspase 1, apoptosis-related cysteine peptidase
Caspase 10, apoptosis-related cysteine peptidase
Caspase 14, apoptosis-related cysteine peptidase
Caspase 2, apoptosis-related cysteine peptidase
Caspase 3, apoptosis-related cysteine peptidase
Caspase 4, apoptosis-related cysteine peptidase
Caspase 5, apoptosis-related cysteine peptidase
Caspase 6, apoptosis-related cysteine peptidase
Caspase 7, apoptosis-related cysteine peptidase
Caspase 8, apoptosis-related cysteine peptidase
Caspase 9, apoptosis-related cysteine peptidase
CD27 molecule
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Jurkat
1.71
1.25
2.18
2.93
1.77
1.25
0.36
0.71
2.14
2.42
2.26
0.29
2.22
0.29
2.38
1.60
0.92
0.81
1.25
1.15
2.07
1.32
1.74
1.62
1.44
1.49
1.11
0.84
1.80
0.35
2.51
1.15
0.77
0.29
1.11
1.97
1.65
1.19
1.74

Nalm-6
-2.14
-1.23
1.32
2.14
1.23
-1.74
2.46
1.32
1.15
1.87
1.00
1.15
-1.74
1.15
1.15
1.23
1.00
-1.15
-1.15
1.87
-1.52
2.00
2.14
1.15
-78.79
-1.23
-1.41
1.15
2.00
1.15
1.15
-1.32
1.07
1.15
-1.15
1.00
34.30
1.52
1.52

Hs.472860
Hs.592244
Hs.715224
Hs.731912
Hs.249129
Hs.708040

NM_001250
NM_000074
NM_001252
NM_003879
NM_001279
NM_014430

CD40
CD40LG
CD70
CFLAR
CIDEA
CIDEB

Hs.591016
Hs.617193
Hs.693441
Hs.484782
Hs.169611
Hs.86131
Hs.244139
Hs.2007
Hs.80409

NM_003805
NM_018947
NM_004938
NM_004401
NM_019887
NM_003824
NM_000043
NM_000639
NM_001924

CRADD
CYCS
DAPK1
DFFA
DIABLO
FADD
FAS
FASLG
GADD45A

Hs.87247
Hs.714012
Hs.193717

NM_003806
NM_000875
NM_000572

HRK
IGF1R
IL10

Hs.36
Hs.1116
Hs.632486
Hs.654500

NM_000595
NM_002342
NM_021960
NM_004536

LTA
LTBR
MCL1
NAIP

Hs.618430
Hs.405153
Hs.513667
Hs.499094
Hs.103755
Hs.241570
Hs.213467
Hs.521456
Hs.81791
Hs.279594
Hs.256278
Hs.443577
Hs.462529
Hs.86447
Hs.478275
Hs.494901
Hs.740601
Hs.523968
Hs.192132
Hs.460996
Hs.522506
Hs.510528
Hs.736565
Hs.534255
Hs.544577

NM_003998
NM_006092
NM_003946
NM_013258
NM_003821
NM_000594
NM_003844
NM_003842
NM_002546
NM_001065
NM_001066
NM_014452
NM_003790
NM_001561
NM_003810
NM_001244
NM_000546
NM_005426
NM_005427
NM_003789
NM_021138
NM_003300
NM_001167
NM_004048
NM_002046

NFKB1
NOD1
NOL3
PYCARD
RIPK2
TNF
TNFRSF10A
TNFRSF10B
TNFRSF11B
TNFRSF1A
TNFRSF1B
TNFRSF21
TNFRSF25
TNFRSF9
TNFSF10
TNFSF8
TP53
TP53BP2
TP73
TRADD
TRAF2
TRAF3
XIAP
B2M
GAPDH

a

CD40 molecule, TNF receptor superfamily member 5
CD40 ligand
CD70 molecule
CASP8 and FADD-like apoptosis regulator
Cell death-inducing DFFA-like effector a
Cell death-inducing DFFA-like effector b
CASP2 and RIPK1 domain containing adaptor with death
domain
Cytochrome c, somatic
Death-associated protein kinase 1
DNA fragmentation factor, 45kDa, alpha polypeptide
Diablo, IAP-binding mitochondrial protein
Fas (TNFRSF6)-associated via death domain
Fas (TNF receptor superfamily, member 6)
Fas ligand (TNF superfamily, member 6)
Growth arrest and DNA-damage-inducible, alpha
Harakiri, BCL2 interacting protein (contains only BH3
domain)
Insulin-like growth factor 1 receptor
Interleukin 10

0.25
2.04
0.59
2.11
0.44
2.07

1.15
2.30
1.15
1.52
1.15
1.32

1.25
2.00
3.48
1.27
1.34
3.36
1.49
0.50
1.41

6.06
1.62
2.00
1.74
1.07
-1.32
1.74
1.15
-2.46

0.55
3.19
0.29

-1.32
1.23
1.15

Lymphotoxin alpha (TNF superfamily, member 1)
Lymphotoxin beta receptor (TNFR superfamily, member 3)
Myeloid cell leukemia sequence 1 (BCL2-related)
NLR family, apoptosis inhibitory protein
Nuclear factor of kappa light polypeptide gene enhancer in Bcells 1
Nucleotide-binding oligomerization domain containing 1
Nucleolar protein 3 (apoptosis repressor with CARD domain)
PYD and CARD domain containing
Receptor-interacting serine-threonine kinase 2
Tumor necrosis factor
Tumor necrosis factor receptor superfamily, member 10a
Tumor necrosis factor receptor superfamily, member 10b
Tumor necrosis factor receptor superfamily, member 11b
Tumor necrosis factor receptor superfamily, member 1A
Tumor necrosis factor receptor superfamily, member 1B
Tumor necrosis factor receptor superfamily, member 21
Tumor necrosis factor receptor superfamily, member 25
Tumor necrosis factor receptor superfamily, member 9
Tumor necrosis factor (ligand) superfamily, member 10
Tumor necrosis factor (ligand) superfamily, member 8
Tumor protein p53
Tumor protein p53 binding protein, 2
Tumor protein p73
TNFRSF1A-associated via death domain
TNF receptor-associated factor 2
TNF receptor-associated factor 3
X-linked inhibitor of apoptosis
Beta-2-microglobulin
Glyceraldehyde-3-phosphate dehydrogenase

1.57
2.38
0.50
1.46

3.48
1.15
2.83
2.30

1.93
2.00
1.71
0.84
0.55
4.07
0.37
2.38
0.29
2.07
0.95
1.65
1.93
0.34
1.74
1.07
1.49
1.97
2.83
3.08
2.11
1.32
1.23
1.02
1.00

-1.15
2.00
24.25
-1.32
-1.00
2.00
1.74
-2.30
1.15
-36.76
1.15
-3.48
1.00
1.15
1.52
-1.00
1.00
1.07
1.15
1.32
-64.00
1.15
-1.23
1.32
1.00

Jurkat and Nalm-6 cells were incubated for 8 hrs with 1µM NC2496 and 1% V/V

DMSO. DMSO and GAPDH were utilized for normalization purposes. Values show in black
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represent a fold regulation of ~1, blue values represent downregulation, and red values represent
upregulation.
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S. Table 3.3: Primers designed for RT-PCR confirmation.
Primer
DAPK1_F

Sequence ( 5' → 3')
CACGACGTCTACTCACAGGC

Gene
DAPK-1

Template
mRNA exon pos. 4397

DAPK1_R

ATGGCGAGAAGGCACCAGTC

DAPK-1

mRNA exon, pos. 4530

TNF-α_F

GAG GCC AAG CCC TGG TAT GA

TNF

mRNA exon pos. 731

TNF-α_R

TGAGTCGGTCACCCTTCTCC

TNF

mRNA exon pos. 800

FADD_F

GAA GAA GAC CTG TGT GCA GCA

FADD

mRNa exon pos. 577

FADD_R

GCTGTGTAGATGCCTGTGGT

FADD

mRNA exon pos. 988

TRADD1_F

TACGAGCGCGAGGGACTGTA

TRADD

mRNA exon pos. 846

TRADD1_R

GGTGAGCTCGTTCTCCTCGA

TRADD

mRNA exon pos. 965

GAPDH-R

GGA AGG ACT CAT GAC CAC AGT

GAPDH

mRNA exon pos.687

GAPDH-F

CAG GGA TGA TGT TCT GGA GAG

GAPDH

mRNA exon pos. 799

R= reverse, F=forward
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Summary and conclusions
The apparition of a first mutation and further cell growth dysregulation is considered the
initiation of cancer. Environmental factors such as the intromission of virus, bacteria, chemical
agents, radiation, and cellular factors like replication errors among others can contribute to
mutations in the DNA by interfering with its correct expression. Additional mutations in the
DNA along the time, formation of new blood vessels, and cooperation among different factors
lead to cancer progression. From these interrelated events is stated that cancer is considered a
broad group of pathologies involving dysregulated cell proliferation, invasion, metastasis, along
with other conditions.
The earlier in stage cancer is detected and treated the better prognosis, because spreading
of mutated cells and organ damage is reduced. Thus, anti-cancer therapies are designed to reduce
invasion and spread of mutated cells. These therapies involve targeted and non-targeted
chemotherapeutic agents. The last, kill cancerous cells and also non-malignant cells with chances
of causing toxicity. While targeted therapies are more directed against cancerous cells. Same
occurs with radiation therapy which can result harmful and not specific, yet new approaches are
being investigated to address specificity. Another strategy for the removal of compromised tissue
is surgery which have shown to be very effective to remove tumors, but it cannot be applied for
all types of cancers, such as in the case of leukemia.
The discovery of novel anti-cancer therapies is always desired to reduce statistics and
developing resistance to current treatments. Thus, additional search of therapies have led to the
isolation and screen of compounds derived from plants and natural sources. In this way,
curcumin (derived from the roots of turmeric) have been identified as an anti-cancer agent with
low toxicity towards normal cells. In vivo testing of curcumin however have show low
bioavailabilty reducing curcumins potential. Thus, to overcome this disadvantage curcumin
analogues have been designed. During the past years, I have being dedicated to research several
curcumin analogues, thus characterizing one lead analogue specific against hematological
malignacies. These lead curcumin analogue was found able to induce selective cytotoxicity at
low micromolar concentration towards hematological malignancies as confirmed by cytotoxicity
assays. Further characterization of this analogue apport findings in where it induces cell death
through TNF-α, cell death receptor mediated apoptosis, and expression of a tumor suppressor
protein. Compared to curcumin or EF-24, this analogue promises better cytotoxicity towards
lymphoma and leukemia, sensitizing these malignancies to apoptosis via intrinsic and extrinsic
pathways and not depending only on one via to affect cancerous cells.Further research should be
conducted to study wether if this analogue causes DNA demethylation for the expression of this
tumor suppressor protein, since it is well-known that this gene coding for this suppessor protein
is frequently methylated in hematological cancers. Further molecules can be designed from this
lead analogue in the expectation of finding even more potent analogues.
In conclusions, curcumin analogues share characteristics related to curcumin’s molecule,
but being a new class of molecules they apport additional features against cancer. Different from
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EF-24, our lead analogue is more apoptotic and this could imply better response and reduced
inflammation. More moleules can be exploited and derivatives of derivatives can be synthetized
in order to find even better anti-cancer compounds. These results support the results of others
and that we can not be wrong to ascribe cytotoxic properties to curcumin and its derivatives.
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